<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Research (Wash D C)</journal-id><journal-id journal-id-type="iso-abbrev">Research (Wash D C)</journal-id><journal-id journal-id-type="publisher-id">RESEARCH</journal-id><journal-title-group><journal-title>Research</journal-title></journal-title-group><issn pub-type="epub">2639-5274</issn><publisher><publisher-name>AAAS</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12099056</article-id><article-id pub-id-type="doi">10.34133/research.0703</article-id><article-id pub-id-type="publisher-id">0703</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="category"><subject>Health Science</subject></subj-group></article-categories><title-group><article-title>Targeting the Exonic Circular <italic toggle="yes">OGT</italic> RNA/O-GlcNAc Transferase/Forkhead Box C1 Axis Inhibits Asparagine- and Alanine-Mediated Ferroptosis Repression in Neuroblastoma Progression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qilan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Yang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Chunhui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Minxiu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaojing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xinyue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Jiaying</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Shunchen</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zheng</surname><given-names>Liduan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="corr1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2615-6404</contrib-id><name><surname>Tong</surname><given-names>Qiangsong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="corr1" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Pediatric Surgery, Union Hospital, Tongji Medical College</addr-line>, 
<institution>Huazhong University of Science and Technology</institution>, Wuhan 430022, Hubei Province, <country>P. R. China</country>.</aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Pathology, Union Hospital, Tongji Medical College</addr-line>, 
<institution>Huazhong University of Science and Technology</institution>, Wuhan 430022, Hubei Province, <country>P. R. China</country>.</aff><aff id="aff3"><label><sup>3</sup></label><addr-line>Department of Geriatrics, Union Hospital, Tongji Medical College</addr-line>, 
<institution>Huazhong University of Science and Technology</institution>, Wuhan 430022, Hubei Province, <country>P. R. China</country>.</aff><author-notes><corresp id="corr1"><label>*</label>Address correspondence to: <email xlink:href="mailto:qstong@mail.hust.edu.cn">qstong@mail.hust.edu.cn</email> (Q.T.); <email xlink:href="mailto:ld_zheng@mail.hust.edu.cn">ld_zheng@mail.hust.edu.cn</email> (L.Z.)</corresp><fn id="afn1"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>8</volume><elocation-id>0703</elocation-id><history>
<date date-type="received"><day>21</day><month>10</month><year>2024</year></date>
<date date-type="rev-recd"><day>16</day><month>4</month><year>2025</year></date>
<date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date>
<date date-type="pub"><day>23</day><month>5</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 Qilan Li et&#x000a0;al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Qilan Li et&#x000a0;al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Exclusive licensee Science and Technology Review Publishing House. No claim to original U.S. Government Works. Distributed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY 4.0)</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="research.0703.pdf"/><abstract><p>The disruption of ferroptosis, an emerging form of programmed cell death, is crucial in the development and aggressiveness of tumors. Meanwhile, the mechanisms and treatments that control ferroptosis in neuroblastoma (NB), a prevalent extracranial cancer in children, are still unknown. In this study, forkhead box C1 (FOXC1) and O-GlcNAc transferase (OGT) are identified as regulators of asparagine- and alanine-mediated ferroptosis repression in NB. Mechanistically, OGT facilitates FOXC1 stabilization via inducing O-GlcNAcylation in liquid condensates to increase the expression of asparagine synthetase (<italic toggle="yes">ASNS</italic>) and glutamate pyruvate transaminase 2 (<italic toggle="yes">GPT2</italic>), resulting in asparagine and alanine biogenesis, and subsequent synthesis of cystathionine &#x003b2;-synthase (CBS) or ferritin heavy chain 1 (FTH1). Meanwhile, exonic circular <italic toggle="yes">OGT</italic> RNA (<italic toggle="yes">ecircOGT</italic>) is able to encode a novel protein (OGT-570aa) containing domain essential for binding of OGT to FOXC1, which competitively decreases the OGT&#x02013;FOXC1 interaction. Preclinically, miconazole nitrate facilitates the interaction of OGT-570aa with FOXC1, suppresses ferroptosis resistance of NB cells, and inhibits their growth, invasion, and metastasis. In clinical NB cases, higher <italic toggle="yes">OGT</italic>, <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, or <italic toggle="yes">FTH1</italic> levels are correlated with worse survival, while lower <italic toggle="yes">ecircOGT</italic> or OGT-570aa expression is associated with tumor progression. These results indicate that targeting the <italic toggle="yes">ecircOGT</italic>/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic> axis inhibits asparagine- and alanine-mediated ferroptosis repression in NB progression.</p></abstract><funding-group specific-use="FundRef"><award-group id="ID0EUGAG27610"><funding-source>
<institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id></institution-wrap>
</funding-source><award-id>82072801, 82293663</award-id><principal-award-recipient>Qiangsong Tong</principal-award-recipient></award-group><award-group id="ID0ERLAG27611"><funding-source>
<institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id></institution-wrap>
</funding-source><award-id>82173316, 82473092</award-id><principal-award-recipient>Liduan Zheng</principal-award-recipient></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><ref-count count="73"/><page-count count="0"/></counts></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Neuroblastoma (NB), the most common extracranial solid malignancy in infants and young children, originates from aberrant neural crest cells and accounts for 10% to 15% of childhood cancer deaths [<xref rid="B1" ref-type="bibr">1</xref>]. Clinically, NB exhibits heterogeneous behaviors including spontaneous regression or rapid progression [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. For high-risk NB patients, despite multimodal treatment such as surgical resection, radiotherapy, high-dose chemotherapy, stem cell transplantation, and immunotherapy, the long-term survival rate is less than 50%, mainly due to tumor relapse or metastasis [<xref rid="B1" ref-type="bibr">1</xref>]. Therefore, a deeper understanding of mechanisms underlying tumorigenesis and aggressiveness is critical for proposing novel strategy of NB treatment.</p><p>Ferroptosis is a type of cell death triggered by lipid reactive oxygen species (ROS) that relies on iron, and is distinct from apoptosis or necroptosis in terms of morphological features [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. In ferroptotic cell death, iron combines with hydrogen peroxide to produce hydroxyl radicals via Fenton reaction [<xref rid="B7" ref-type="bibr">7</xref>], a process facilitated by autophagic breakdown of iron-storing ferritin heavy chain 1 (FTH1) [<xref rid="B8" ref-type="bibr">8</xref>]. Besides, amino acids modulate ferroptosis through &#x0200c;maintaining redox homeostasis [<xref rid="B9" ref-type="bibr">9</xref>]. Among them, cysteine is an essential precursor of glutathione (GSH) that is critical for detoxifying lipid peroxides via glutathione peroxidase 4 (GPX4)-mediated conversion to oxidized glutathione (GSSG) [<xref rid="B10" ref-type="bibr">10</xref>], while GSSG is transformed back to GSH by consuming nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) [<xref rid="B10" ref-type="bibr">10</xref>]. As an important component of trans-sulfuration pathway, cystathionine &#x003b2;-synthase (CBS) converts homocysteine to cysteine [<xref rid="B11" ref-type="bibr">11</xref>] and mediates resistance to ferroptosis in liver [<xref rid="B11" ref-type="bibr">11</xref>], breast [<xref rid="B12" ref-type="bibr">12</xref>], or ovarian [<xref rid="B13" ref-type="bibr">13</xref>] cancer. <italic toggle="yes">CBS</italic> fosters the development and aggressiveness of colon cancer [<xref rid="B14" ref-type="bibr">14</xref>], whereas lower <italic toggle="yes">CBS</italic> levels are linked to glioma progression [<xref rid="B15" ref-type="bibr">15</xref>], indicating its oncogenic or tumor-suppressive functions depending on the context. Nevertheless, additional investigation is required to explore the molecular basis and treatment approaches that control ferroptosis in tumor progression.</p><p>Forkhead box C1 (FOXC1) belongs to the FOX transcription factor family featured by a winged helix DNA-binding domain [<xref rid="B16" ref-type="bibr">16</xref>] and participates in embryonic development, proliferation, or metabolism [<xref rid="B16" ref-type="bibr">16</xref>]. Abnormal expression of <italic toggle="yes">FOXC1</italic> is documented in liver [<xref rid="B17" ref-type="bibr">17</xref>], gastric [<xref rid="B18" ref-type="bibr">18</xref>], esophageal [<xref rid="B19" ref-type="bibr">19</xref>], or prostate [<xref rid="B20" ref-type="bibr">20</xref>] cancer, and is linked to unfavorable outcomes of patients [<xref rid="B17" ref-type="bibr">17</xref>]. As a transcription factor, FOXC1 promotes tumor invasion or metastasis by increasing the expression of neural precursor cell expressed developmentally down-regulated 9 (<italic toggle="yes">NEDD9</italic>) [<xref rid="B17" ref-type="bibr">17</xref>] or matrix metalloprotease 7 (<italic toggle="yes">MMP7</italic>) [<xref rid="B21" ref-type="bibr">21</xref>]. In hepatocellular carcinoma (HCC), <italic toggle="yes">FOXC1</italic> facilitates C-C motif chemokine ligand 2 (<italic toggle="yes">CCL2</italic>) or C-X-C motif chemokine receptor 1 (<italic toggle="yes">CXCR1</italic>) expression to drive tumor-associated macrophage infiltration and metastasis [<xref rid="B22" ref-type="bibr">22</xref>]. In addition, <italic toggle="yes">FOXC1</italic> regulates stem cell properties via activating smoothened-independent Hedgehog signaling in breast cancer [<xref rid="B23" ref-type="bibr">23</xref>]. The expression or activity of <italic toggle="yes">FOXC1</italic> is controlled at posttranslational levels [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>]. Extracellular signal-regulated kinase 1/2 (ERK1/2) induces S272 phosphorylation and prolongs half-life of FOXC1 protein in cervical cancer [<xref rid="B24" ref-type="bibr">24</xref>], while SUMOylation of FOXC1 inhibits its transcriptional activity [<xref rid="B25" ref-type="bibr">25</xref>]. These findings indicate that <italic toggle="yes">FOXC1</italic> exerts oncogenic functions, while its targets and regulatory mechanisms in ferroptosis still need to be identified.</p><p>In this research, we discover that <italic toggle="yes">FOXC1</italic> enhances the expression of de novo asparagine or alanine biogenesis genes, asparagine synthetase (<italic toggle="yes">ASNS</italic>) and glutamate pyruvate transaminase 2 (<italic toggle="yes">GPT2</italic>), which are linked to poor prognosis of NB patients. Notably, amino acid deprivation triggers direct interaction of O-GlcNAc transferase (OGT) with FOXC1 in liquid condensates, resulting in O-GlcNAcylation and stabilization of FOXC1 to resist ferroptosis via increasing asparagine/alanine biogenesis and subsequent CBS or FTH1 expression. Meanwhile, a novel protein consisting of 570 amino acids (OGT-570aa) encoded by exonic circular <italic toggle="yes">OGT</italic> RNA (<italic toggle="yes">ecircOGT</italic>) is able to competitively bind with FOXC1, leading to a decrease in OGT&#x02013;FOXC1 interaction, <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> expression, asparagine and alanine biogenesis, and ferroptosis resistance of NB cells. Preclinically, administration of miconazole nitrate (MN) facilitates the interaction of OGT-570aa with FOXC1, and inhibits the growth and severity of tumors, indicating the roles of the <italic toggle="yes">ecircOGT</italic>/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic> axis in asparagine/alanine biogenesis and ferroptosis resistance during NB progression.</p></sec><sec id="sec2"><title>Results</title><sec id="sec3"><title><italic toggle="yes">FOXC1</italic> facilitates asparagine and alanine biogenesis in tumor cells</title><p>To investigate the mechanisms regulating tumorigenesis, RNA sequencing (RNA-seq) assay was performed to show 1,118 elevated and 1,392 reduced genes in SH-SY5Y, an established NB cell line model for neuronal response to nutrition deprivation [<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>], after treatment by Earle&#x02019;s balanced salt solution (EBSS) free of amino acids (Fig. <xref rid="F1" ref-type="fig">1</xref>A). Through mining of a publicly available dataset of 498 NB patients (GSE62564), 903 genes were consistently linked to different stages of mortality, risk stratification, clinical advancement, and events (Fig. <xref rid="F1" ref-type="fig">1</xref>A). Gene set enrichment analysis (GSEA) showed obvious involvement of these genes in amino acid metabolism or cell growth with a normalized enrichment score (NES) of 1.61 (normalized <italic toggle="yes">P</italic> value &#x0003c; 1.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;4</sup>) or 1.45 (normalized <italic toggle="yes">P</italic> value &#x0003c; 1.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;4</sup>), especially in Asp/Glu, serine (Ser), or Cys/methionine (Met) metabolism (Fig. <xref rid="F1" ref-type="fig">1</xref>B). Analysis using the ChIP-X program [<xref rid="B28" ref-type="bibr">28</xref>] indicated top 5 transcriptional regulators of these amino acid metabolic genes, including FOXC1, GATA binding protein 2 (GATA2), breast cancer gene 1 (BRCA1), Jun proto-oncogene (JUN), and KLF transcription factor 13 (KLF13; Fig. <xref rid="F1" ref-type="fig">1</xref>B and Table <xref rid="supplementary-material-1" ref-type="sec">S1</xref>). Further analysis of public datasets revealed that only <italic toggle="yes">FOXC1</italic> was consistently associated with poor survival of 498 (GSE62564), 283 (GSE85047), 102 (GSE3446), and 88 (GSE16476) NB patients (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>A). In cultured NB cells, supplements of alanine (Ala), asparagine (Asn), aspartate, cysteine, glutamine, or glutamate were able to resist cell death triggered by inducers of ferroptosis (erastin) or autophagy (rapamycin), but not by those of apoptosis (cisplatin) or cuproptosis (elesclomol, Fig. <xref rid="F1" ref-type="fig">1</xref>C). The activity, but not transcript levels, of <italic toggle="yes">FOXC1</italic> was enhanced by EBSS treatment (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>B and C). Western blot assay showed the increase of FOXC1 levels within cultured NB cell lines, prostate cancer PC-3 cells, and cervical cancer HeLa cells, when compared to those in embryonic kidney HEK293 cells (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>D). Based on endogenous FOXC1 levels, SH-SY5Y, SK-N-AS, PC-3 (exhibiting relatively low expression), SK-N-BE(2), IMR-32, and HeLa (with relatively high expression) cell lines were selected for further investigation (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>D). Steady overexpression or silencing of <italic toggle="yes">FOXC1</italic> resulted in higher or lower levels of <italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic> transcripts, without alteration in those of <italic toggle="yes">CBS</italic> or glutamate-cysteine ligase modifier subunit (<italic toggle="yes">GCLM</italic>, Fig. <xref rid="F1" ref-type="fig">1</xref>D). In 498 NB patients (GSE62564), the levels of <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, or <italic toggle="yes">GPT2</italic> were linked to risk stratification, survival status, and survival duration (Fig. <xref rid="F1" ref-type="fig">1</xref>E). Mining of a chromatin immunoprecipitation sequencing (ChIP-seq) dataset (GSE209112) revealed that FOXC1 was endogenously enriched on promoter regions of <italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic> (Fig. <xref rid="F1" ref-type="fig">1</xref>F). Dual-luciferase reporter, chromatin immunoprecipitation (ChIP), and Western blotting studies uncovered that steady overexpression or silencing of <italic toggle="yes">FOXC1</italic> into NB cells led to an increase or decrease in FOXC1 activity (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>E), FOXC1 enrichment (Fig. <xref rid="F1" ref-type="fig">1</xref>G), and protein levels of <italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic> (Fig. <xref rid="F1" ref-type="fig">1</xref>H and Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>F). In cultured PC-3 and HeLa cells, ectopic expression or knockdown of <italic toggle="yes">FOXC1</italic> also resulted in the up-regulation or down-regulation of <italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic>, respectively (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>G and H). Of note, the levels of asparagine, alanine, and <sup>13</sup>C<sub>5</sub>-glutamine metabolites were increased or reduced within SH-SY5Y and SK-N-BE(2) cell lines that were permanently transfected by <italic toggle="yes">FOXC1</italic> or short hairpin RNAs (shRNAs) targeting <italic toggle="yes">FOXC1</italic> (sh-FOXC1, Fig. <xref rid="F1" ref-type="fig">1</xref>I to K). There was an increase or decrease in asparagine and alanine levels in PC-3 and HeLa cells with overexpression or silencing of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>I). Interestingly, EBSS treatment facilitated FOXC1 protein levels in NB cells (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>J). The above findings suggested that <italic toggle="yes">FOXC1</italic> facilitated asparagine and alanine biogenesis in tumor cells.</p><fig position="float" id="F1"><label>Fig. 1.</label><caption><p><italic toggle="yes">FOXC1</italic> facilitates asparagine and alanine biogenesis in NB cells. (A) Volcano plot (left panel) showing differentially expressed genes (fold change &#x0003e;2.0, <italic toggle="yes">P</italic> &#x0003c; 0.01) in SH-SY5Y cells treated with control (CTL) DMEM/F12 or EBSS for 6 h. Venn diagram (middle panel) and GSEA (right panels) revealing their association with death, high risk, clinical progression, and event in 498 NB cases (GSE62564), as well as biological functions. (B) KEGG pathway analysis (top panel) and ChIP-X program (bottom panel) revealing the involvement and transcriptional regulators of amino acid metabolic genes. (C) MTT colorimetric assay indicating the viabilities of SH-SY5Y cells treated with amino acids (AA), AA deprivation [AA(&#x02212;)], or supplement of alanine (Ala), arginine (Arg), asparagine (Asn), aspartate (Asp), cysteine (Cys), glutamine (Gln), glutamate (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), or valine (Val), and those treated with DMSO, erastin (5.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>), rapamycin (1.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>), cisplatin (5.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>), or elesclomol (20 nmol&#x000b7;l<sup>&#x02212;1</sup>) for 16 h. (D) Real-time qRT-PCR assay indicating the levels (normalized to <italic toggle="yes">&#x003b2;-actin</italic>, <italic toggle="yes">n</italic> = 5) of <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, <italic toggle="yes">CBS</italic>, <italic toggle="yes">GCLM</italic>, or <italic toggle="yes">GPT2</italic> in SH-SY5Y or SK-N-BE(2) cells stably transfected with empty vector (mock), <italic toggle="yes">FOXC1</italic>, scramble shRNA (sh-Scb), sh-FOXC1 #1, or sh-FOXC1 #2. (E) Heatmap indicating the expression profiles of <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, or <italic toggle="yes">GPT2</italic> in 498 NB cases (GSE62564) with different risk stratification, alive status, or survival time. (F) ChIP-seq peak (GSE209112) revealing endogenous enrichment of FOXC1 on promoter regions of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in HepG2 cells. (G and H) ChIP-qPCR (G, normalized to input, <italic toggle="yes">n</italic> = 3) and Western blot (H) assays revealing the FOXC1 enrichment or expression levels of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in SH-SY5Y or SK-N-BE(2) cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, sh-Scb, sh-FOXC1 #1, or sh-FOXC1 #2. (I) Relative asparagine and alanine levels in SH-SY5Y or SK-N-BE(2) cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, sh-Scb, sh-FOXC1 #1, or sh-FOXC1 #2 (<italic toggle="yes">n</italic> = 5). (J and K) Schematic illustration, heatmap (J), and quantification (K) of <sup>13</sup>C-glutamine metabolic flux assay indicating the levels of metabolites within SK-N-BE(2) cells stably transfected with sh-Scb, or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 3). Fisher&#x02019;s exact test for overlapping analysis in (A). Student&#x02019;s <italic toggle="yes">t</italic> test or ANOVA compared the difference in (D), (G), (I), and (K). *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (D) to (K).</p></caption><graphic xlink:href="research.0703.fig.001" position="float"/></fig></sec><sec id="sec4"><title><italic toggle="yes">FOXC1</italic> promotes ferroptosis repression and NB progression via asparagine/alanine-facilitated CBS and FTH1 synthesis</title><p>Since asparagine and alanine are essential amino acids for protein synthesis [<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>], O-propargyl-puromycin (OP-Puro) and puromycin incorporation assays were performed to reveal the increase or decrease of global protein synthesis within SH-SY5Y and SK-N-BE(2) cells exhibiting excessive expression or knockdown of <italic toggle="yes">FOXC1</italic>, respectively (Fig. <xref rid="F2" ref-type="fig">2</xref>A and B). In polysome profiling assay, asparagine and alanine supplement led to 618 increased and 566 decreased translating mRNAs associated with polysomes in lysates of SK-N-BE(2) cells (Fig. <xref rid="F2" ref-type="fig">2</xref>C and Tables <xref rid="supplementary-material-1" ref-type="sec">S2</xref> and <xref rid="supplementary-material-1" ref-type="sec">S3</xref>), while 11 of them were substantially associated with ferroptosis and death, high risk, clinical progression, or events in 498 (GSE62564) cases of NB (Fig. <xref rid="F2" ref-type="fig">2</xref>C), including CBS and FTH1 (Fig. <xref rid="F2" ref-type="fig">2</xref>D). Consistent with the roles of CBS in facilitating GSH synthesis and GPX4 activity [<xref rid="B11" ref-type="bibr">11</xref>], stable ectopic expression of <italic toggle="yes">FOXC1</italic> increased the GSH/GSSG ratio (Fig. <xref rid="F2" ref-type="fig">2</xref>E), GPX4 activity (Fig. <xref rid="F2" ref-type="fig">2</xref>F), or NADPH/nicotinamide adenine dinucleotide phosphate (NADP<sup>+</sup>) ratio (Fig. <xref rid="F2" ref-type="fig">2</xref>G) in SH-SY5Y cells, which were abolished by treatment with aminooxyacetic acid (AOAA), an established inhibitor of CBS (Fig. <xref rid="F2" ref-type="fig">2</xref>E to G), without alteration in <italic toggle="yes">CBS</italic> or <italic toggle="yes">FTH1</italic> transcript levels (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>K). In addition, the decrease of free liable iron levels induced by <italic toggle="yes">FOXC1</italic> overexpression was reversed by treatment with FTH1 inhibitor D3-3 [<xref rid="B31" ref-type="bibr">31</xref>] (Fig. <xref rid="supplementary-material-1" ref-type="sec">S1</xref>L).</p><fig position="float" id="F2"><label>Fig. 2.</label><caption><p><italic toggle="yes">FOXC1</italic> promotes ferroptosis repression and NB progression via asparagine/alanine-facilitated CBS and FTH1 synthesis. (A and B) OP-puro (A) and puromycin (B) incorporation assays in SH-SY5Y or SK-N-BE(2) cells stably transfected with empty vector (mock), <italic toggle="yes">FOXC1</italic>, scramble shRNA (sh-Scb), sh-FOXC1 #1, or sh-FOXC1 #2. Scale bars: 10 &#x003bc;m. (C) Schematic illustration (left panel), sucrose gradient sedimentation (middle panel), volcano plot (middle panel), and Venn diagram (right panel) indicating the polysome profiling of mRNA translation altered in SK-N-BE(2) cells with asparagine/alanine (Asn/Ala) supplement or deprivation, and those associated with ferroptosis or death, high risk, clinical progression, and event in 498 NB cases (GSE62564). (D) Schematic illustration showing the impact of CBS, FTH1, and their inhibitors (AOAA or D3-3) on ferroptosis as indicated. (E to G) Relative GSH/GSSG ratio (E), GPX4 activity (F), and NADPH/NADP<sup>+</sup> ratio (G) in SH-SY5Y cells stably transfected with mock or <italic toggle="yes">FOXC1</italic>, and those treated with DMSO or AOAA (1.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>). (H) In&#x000a0;vivo imaging (left panel), growth curve (middle panel), weight at the end points (middle panel), and asparagine and alanine levels (right panel) of xenograft tumors in nude mice formed by subcutaneous injection of SH-SY5Y cells stably transfected with mock or <italic toggle="yes">FOXC1</italic>, and those treated with asparagine/alanine (A/A)-free diet or erastin (0.5 nmol&#x000b7;l<sup>&#x02212;1</sup> per mouse, <italic toggle="yes">n</italic> = 5 for each group). (I) In&#x000a0;vivo imaging (left panel), HE staining and quantification of lung metastasis (middle panels), and Kaplan&#x02013;Meier curves (right panel) of nude mice treated with vein tail injection of SH-SY5Y cells stably transfected with mock or <italic toggle="yes">FOXC1</italic>, and those treated with A/A-free diet or erastin (0.5 nmol&#x000b7;l<sup>&#x02212;1</sup> per mouse, <italic toggle="yes">n</italic> = 5 for each group). Student&#x02019;s <italic toggle="yes">t</italic> test or ANOVA compared the difference in (A) and (E) to (I). Log-rank test for survival comparison in (I). *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (A) to (I).</p></caption><graphic xlink:href="research.0703.fig.002" position="float"/></fig><p>Rescue studies were carried out to disclose the contribution of asparagine and alanine to <italic toggle="yes">FOXC1</italic>-induced tumor growth or aggressiveness. Asparagine and alanine deprivation abolished the elevation in GSH/GSSG ratio, GPX4 activity, or NADPH/NADP<sup>+</sup> ratio, reduction in lipid ROS levels, and increase in mitochondrial membrane potential, proliferation, and invasion of NB cells exhibiting excessive expression of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="supplementary-material-1" ref-type="sec">S2</xref>A to G). To evaluate the influence of <italic toggle="yes">FOXC1</italic> on the formation of tumors, SH-SY-5Y cells were injected either under the skin or into the tail vein of athymic nude mice. Small animal imaging test showed the increase of fluorescence levels in subcutaneous tumors produced by NB cells receiving stable <italic toggle="yes">FOXC1</italic> transfection (Fig. <xref rid="F2" ref-type="fig">2</xref>H). There was a notable increase in growth, mass, target gene (<italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, and <italic toggle="yes">FTH1</italic>) expression, Ki-67 expression, CD31-staining microvessels, and asparagine or alanine levels in xenograft tumors implanted under the skin of nude mice generated by SH-SY5Y cells with consistent transfection of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="F2" ref-type="fig">2</xref>H and Fig. <xref rid="supplementary-material-1" ref-type="sec">S3</xref>A and B). In the experimental metastasis assay, athymic mice injected with SH-SY-5Y cells overexpressing <italic toggle="yes">FOXC1</italic> via the tail vein showed stronger fluorescence signals, more lung metastasis, and less survival rates (Fig. <xref rid="F2" ref-type="fig">2</xref>I). In the meantime, these in&#x000a0;vivo changes caused by <italic toggle="yes">FOXC1</italic> overexpression were reversed by administration of asparagine- and alanine-free diet or erastin (Fig. <xref rid="F2" ref-type="fig">2</xref>H and I and Fig. <xref rid="supplementary-material-1" ref-type="sec">S3</xref>A and B). These findings showed that <italic toggle="yes">FOXC1</italic> enhanced ferroptosis repression and NB progression via asparagine/alanine-facilitated CBS and FTH1 synthesis.</p></sec><sec id="sec5"><title>OGT physically interacts with FOXC1 in NB cells</title><p>To determine the crucial FOXC1 protein partners, co-immunoprecipitation (co-IP) using FOXC1 antibody and subsequent proteomics tests were conducted, identifying 335 candidates within IMR-32 cell lysates (Fig. <xref rid="F3" ref-type="fig">3</xref>A and Table <xref rid="supplementary-material-1" ref-type="sec">S4</xref>). Based on the evidence showing an increase in FOXC1 protein levels due to amino acid deprivation, we hypothesized that its protein partner involved in posttranslational modification (PTM) might regulate this process. By comparing mass spectrometry data with those essential for deubiquitination process and PTM enzymes from the AmiGO2 database (<ext-link xlink:href="http://amigo.geneontology.org/" ext-link-type="uri">http://amigo.geneontology.org/</ext-link>), 3 proteins were identified, including defective in cullin neddylation 1 domain containing 1 (DCUN1D1), OGT, and ring box protein 1 (RBX1, Fig. <xref rid="F3" ref-type="fig">3</xref>A). Validating co-IP along with molecular docking studies indicated the binding of FOXC1 to OGT, but not to DCUN1D1 or RBX1, in IMR-32 cells (Fig. <xref rid="F3" ref-type="fig">3</xref>B and C). Immunofluorescence test indicated nuclear colocalization of OGT and FOXC1 in SH-SY-5Y cells, which was promoted by overexpression of either <italic toggle="yes">OGT</italic> or <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="F3" ref-type="fig">3</xref>D). By using recombinant glutathione <italic toggle="yes">S</italic>-transferase (GST)-tagged OGT and maltose binding protein (MBP)-tagged FOXC1 proteins, co-IP as well as Western blotting studies showed that the tetratricopeptide repeat (TPR) domain (1 to 473 amino acids) of OGT and activation domain 1 (AD1, 1 to 68 amino acids) of FOXC1 were essential for their interaction (Fig. <xref rid="F3" ref-type="fig">3</xref>E), which was further validated in SH-SY5Y cells transfected by truncation constructs of hemagglutinin (HA)-tagged <italic toggle="yes">OGT</italic> and Flag-tagged <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="supplementary-material-1" ref-type="sec">S4</xref>A and B). In a bimolecular fluorescence complementation (BiFC) experiment, a physical interplay between OGT and FOXC1 was observed within the SH-SY5Y cell line transfected by their corresponding constructs (Fig. <xref rid="supplementary-material-1" ref-type="sec">S4</xref>C). According to structural analysis using the HDOCK program [<xref rid="B32" ref-type="bibr">32</xref>], mutation of the 296th residue in the TPR domain of OGT or 66th and 67th residues in the AD1 domain of FOXC1 disrupted their interaction (Fig. <xref rid="F3" ref-type="fig">3</xref>E and Fig. <xref rid="supplementary-material-1" ref-type="sec">S4</xref>C). These findings showed that there was a physical interaction between OGT and FOXC1 in NB cells.</p><fig position="float" id="F3"><label>Fig. 3.</label><caption><p>OGT physically interacts with FOXC1 in NB cells. (A) SDS-PAGE and Coomassie blue staining (left panel) of proteins immunoprecipitated by FOXC1 antibody from IMR-32 cell lysates, while Venn diagram (right panel) showing identification of FOXC1 protein partner by overlapping analysis of mass spectrometry (MS) results with those involved in deubiquitination process and PTM enzymes derived from the AmiGO2 (<ext-link xlink:href="http://amigo.geneontology.org/" ext-link-type="uri">http://amigo.geneontology.org/</ext-link>) database. (B) Co-IP and Western blot assays indicating the interaction of FOXC1 with DCUN1D1, OGT, or RBX1 in IMR-32 cells. (C) Analysis of 3-dimensional (3D) structures of OGT and FOXC1 via the HDOCK program (<ext-link xlink:href="http://hdock.phys.hust.edu.cn" ext-link-type="uri">http://hdock.phys.hust.edu.cn</ext-link>). (D) Immunofluorescent observation revealing colocalization of OGT and FOXC1 proteins (arrowheads) in SH-SY5Y cells transfected with empty vector (mock), <italic toggle="yes">OGT</italic>, or <italic toggle="yes">FOXC1</italic>. Scale bars: 10 &#x003bc;m. (E) Co-IP and Western blot assays (bottom panels) indicating the interaction between wild-type or truncations of recombinant GST-tagged <italic toggle="yes">OGT</italic> and MBP-tagged <italic toggle="yes">FOXC1</italic> proteins, and that in SH-SY5Y cells transfected with wild-type (WT) or mutant (Mut) HA-tagged <italic toggle="yes">OGT</italic> and FLAG-tagged <italic toggle="yes">FOXC1</italic> truncations as indicated (top panels). Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (B), (D), and (E).</p></caption><graphic xlink:href="research.0703.fig.003" position="float"/></fig></sec><sec id="sec6"><title>Liquid OGT/FOXC1 condensates promote asparagine/alanine-mediated ferroptosis repression and NB progression</title><p>Following the identification of intrinsically disordered regions (IDRs), consisting of 1 to 78 and 141 to 553 amino acid residues, within FOXC1 protein using the Preditor of Natural Disordered Regions program [<xref rid="B33" ref-type="bibr">33</xref>] (Fig. <xref rid="F4" ref-type="fig">4</xref>A), further studies on the potential liquid&#x02013;liquid phase separation (LLPS) of FOXC1 and OGT proteins were carried out. In&#x000a0;vitro droplet formation test of recombinant OGT (mCherry-tagged) and FOXC1 (mEGFP-tagged) proteins (purity&#x0003e;90%) showed their aggregation into droplets, resembling the compartment observed in the SK-N-AS cell line, which was abated following deletion of FOXC1 IDR or treatment with 1,6-hexanediol (1,6-Hex), an established inhibitor of LLPS [<xref rid="B34" ref-type="bibr">34</xref>] (Fig. <xref rid="F4" ref-type="fig">4</xref>A and B and Fig. <xref rid="supplementary-material-1" ref-type="sec">S5</xref>A and B). The fluorescence recovery after photobleaching (FRAP) assay was used to investigate the fluid characteristics of OGT and FOXC1 within condensates, showing quick exchange kinetics (Fig. <xref rid="F4" ref-type="fig">4</xref>C and Fig. <xref rid="supplementary-material-1" ref-type="sec">S5</xref>C). There was a decrease in FOXC1 activity, enrichment, and transcript or protein levels of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in SK-N-AS cells with stable <italic toggle="yes">OGT</italic> silencing, accompanied by down-regulation of CBS and FTH1, while ectopic expression of <italic toggle="yes">FOXC1</italic> prevented this effect (Fig. <xref rid="supplementary-material-1" ref-type="sec">S6</xref>A to C). Meanwhile, the interplay of <italic toggle="yes">OGT</italic> and <italic toggle="yes">FOXC1</italic> in gene expression was abolished by 1,6-Hex treatment (Fig. <xref rid="supplementary-material-1" ref-type="sec">S6</xref>A to C).</p><fig position="float" id="F4"><label>Fig. 4.</label><caption><p>Liquid OGT/FOXC1 condensates promote asparagine/alanine-mediated ferroptosis repression and NB progression. (A) IDR within FOXC1 protein analyzed by the PONDR (<ext-link xlink:href="http://www.pondr.com/" ext-link-type="uri">http://www.pondr.com/</ext-link>) program (bottom left panel), with fluorescence imaging assay indicating the condensate formation of recombinant OGT-mCherry proteins and full-length (FL) or IDR-deficient (&#x00394;IDR) FOXC1-EGFP (right panel) as indicated (top left panel). (B) Fluorescence imaging assay showing the condensate formation of recombinant OGT-mCherry and FOXC1-EGFP proteins, in the presence or absence of 1.5% 1,6-Hex. (C) Representative images (left panel) and quantification (right panel) of FRAP assay indicating the exchange kinetics of OGT-mCherry and FOXC1-EGFP within condensates. Scale bars: 10 &#x003bc;m. (D to F) Relative asparagine and alanine levels (D), GSH/GSSG ratio (E), and NADPH/NADP<sup>+</sup> ratio (F) in SK-N-BE(2) cells stably transfected with empty vector (mock) or <italic toggle="yes">OGT</italic>, and those transfected with scramble shRNA (sh-Scb) or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 3). (G) Representative images (left panel) and quantification (right panel) of RhoNox-1 staining in SK-N-BE(2) cells stably transfected with mock or <italic toggle="yes">OGT</italic>, and those stably transfected with sh-Scb or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 3). Scale bars: 10 &#x003bc;m. (H) Flow cytometry showing the lipid ROS levels in SK-N-BE(2) cells stably transfected with mock or <italic toggle="yes">OGT</italic>, and those stably transfected with sh-Scb or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 3). (I) Representative images (left panel) and quantification (right panel) of JC-1 (2&#x02009;&#x003bc;g&#x000b7;ml<sup>&#x02212;1</sup>) staining in SK-N-BE(2) cells stably transfected with mock or <italic toggle="yes">OGT</italic>, and those stably transfected with sh-Scb or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 5). Scale bars: 10 &#x003bc;m. (J) Growth curve (left panel), weight at the end points (middle panel), and asparagine or alanine levels (right panel) of subcutaneous xenograft tumors in nude mice formed by SK-N-BE(2) cells stably transfected with mock or <italic toggle="yes">OGT</italic>, and those transfected with sh-Scb or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 5 for each group). (K) Kaplan&#x02013;Meier curves of nude mice treated with tail vein injection of SK-N-BE(2) cells stably transfected with mock or <italic toggle="yes">OGT</italic>, and those transfected with sh-Scb or sh-FOXC1 #1 (<italic toggle="yes">n</italic> = 5 for each group). ANOVA compared the difference in (D) to (G), (I), and (J). Log-rank test for survival comparison in (K). *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (A) to (K).</p></caption><graphic xlink:href="research.0703.fig.004" position="float"/></fig><p>We next investigated functional interplay of <italic toggle="yes">OGT</italic> and <italic toggle="yes">FOXC1</italic> in asparagine/alanine biogenesis essential for ferroptosis repression and tumor progression. Stable ectopic expression of <italic toggle="yes">OGT</italic> elevated the asparagine and alanine levels (Fig. <xref rid="F4" ref-type="fig">4</xref>D), GSH/GSSG ratio (Fig. <xref rid="F4" ref-type="fig">4</xref>E), or NADPH/NADP<sup>+</sup> ratio (Fig. <xref rid="F4" ref-type="fig">4</xref>F); reduced the free liable iron and lipid ROS levels (Fig. <xref rid="F4" ref-type="fig">4</xref>G and H); and increased the mitochondrial membrane potential in SK-N-BE(2) cells (Fig. <xref rid="F4" ref-type="fig">4</xref>I), whereas these effects were reversed by lowering <italic toggle="yes">FOXC1</italic> levels (Fig. <xref rid="F4" ref-type="fig">4</xref>D to I). The proliferative and invasive capabilities of SK-N-BE(2) cells were enhanced following forced excessive expression of <italic toggle="yes">OGT</italic>, but these effects were reversed when <italic toggle="yes">FOXC1</italic> was silenced (Fig. <xref rid="supplementary-material-1" ref-type="sec">S6</xref>D and E). In nude mice, stable overexpression of <italic toggle="yes">OGT</italic> into SK-N-BE(2) cells facilitated the growth, weight, downstream gene (<italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, and <italic toggle="yes">FTH1</italic>) expression, Ki-67 expression, CD31-staining microvessels, and asparagine or alanine abundance of subcutaneous xenograft tumors, which were hindered due to silencing of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="F4" ref-type="fig">4</xref>J and Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>A to C). Athymic nude mice injected with SK-N-BE(2) cells with excessive <italic toggle="yes">OGT</italic> expression via tail vein had increased lung metastatic colonies and a lower chance of survival. However, these effects were reversed when <italic toggle="yes">FOXC1</italic> was knocked down (Fig. <xref rid="F4" ref-type="fig">4</xref>K and Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>D). These findings suggested that liquid FOXC1/OGT condensates promoted asparagine/alanine-mediated ferroptosis repression and NB progression.</p></sec><sec id="sec7"><title>OGT stabilizes FOXC1 protein via O-GlcNAcylation in NB cells</title><p>To investigate the mechanisms regulating FOXC1 expression, we further observed the impact of OGT on FOXC1 protein stability. Stable silencing of <italic toggle="yes">OGT</italic> resulted in the decrease of FOXC1 levels within the SH-SY5Y cell line pretreated by cycloheximide (CHX), an acknowledged protein synthesis inhibitor (Fig. <xref rid="F5" ref-type="fig">5</xref>A). In addition, a proteasome inhibitor (MG132) was able to rescue the decrease of FOXC1 protein levels in NB cells treated with <italic toggle="yes">OGT</italic> knockdown or OGT inhibitor (OSMI-1) [<xref rid="B35" ref-type="bibr">35</xref>] (Fig. <xref rid="F5" ref-type="fig">5</xref>B and C). Interestingly, EBSS treatment substantially increased the OGT binding and O-GlcNAcylation of FOXC1 in the SK-N-BE(2) cell line (Fig. <xref rid="F5" ref-type="fig">5</xref>D). Increased or reduced O-GlcNAcylation and expression levels of FOXC1 were observed within NB cell lines with excessive expression or silencing of <italic toggle="yes">OGT</italic> (Fig. <xref rid="F5" ref-type="fig">5</xref>E). To further assess O-GlcNAcylation of FOXC1 protein, in&#x000a0;vitro O-GlcNAcylation assay was performed, which revealed the direct O-GlcNAcylation of MBP-tagged FOXC1 protein by GST-tagged OGT, while incubation of O-GlcNAcase (OGA) abolished these effects (Fig. <xref rid="F5" ref-type="fig">5</xref>F). Notably, the stability of FOXC1 protein was facilitated or decreased in SK-N-BE(2) and SH-SY5Y lines receiving treatment of TMG (an activator of O-GlcNAcylation) [<xref rid="B36" ref-type="bibr">36</xref>] or OSMI-1, respectively (Fig. <xref rid="F5" ref-type="fig">5</xref>G and H). Next, we further explored the amino acid residues essential for O-GlcNAcylation of FOXC1. Based on analysis using the O-GlcNAcPRED-DL tool [<xref rid="B37" ref-type="bibr">37</xref>], mutation of the 8th serine, but not of the 68th threonine, of FOXC1 led to a decrease of its O-GlcNAcylation, transcriptional activity, and enrichment on target genes, resulting in the down-regulation of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in NB cells (Fig. <xref rid="F5" ref-type="fig">5</xref>I to L). These results suggested that OGT stabilized FOXC1 protein via O-GlcNAcylation (Fig. <xref rid="F5" ref-type="fig">5</xref>M) in NB cells.</p><fig position="float" id="F5"><label>Fig. 5.</label><caption><p>OGT stabilizes FOXC1 protein via O-GlcNAcylation in NB cells. (A) Western blot assay showing the FOXC1 levels in SH-SY5Y cells stably transfected with scramble shRNA (sh-Scb) or sh-OGT #1, and those treated with CHX (20 &#x003bc;g&#x000b7;ml<sup>&#x02212;1</sup>) as indicated. (B and C) Western blot assay indicating the expression of OGT and FOXC1 in SH-SY5Y cells stably transfected with sh-Scb or sh-OGT #1 (B) or incubated with OSMI-1 (C, 2.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>), and those treated with MG132 (10 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>) for 4 h. (D) Co-IP and Western blot assays revealing the binding of OGT to FOXC1 and FOXC1 O-GlcNAcylation in SH-SY5Y cells treated with control (CTL) DMEM/F12 or EBSS for 6 h. (E) Co-IP and Western blot assays showing the O-GlcNAcylation of FOXC1 in SH-SY5Y cells stably transfected with empty vector (mock), OGT, sh-Scb, sh-OGT #1, or sh-OGT #2. (F) In&#x000a0;vitro O-glcNAcylation assay indicating the O-glcNAcylation of MBP-tagged FOXC1 protein in the presence of UDP-GlcNAc, GST-tagged OGT, or OGA. (G and H) Western blot assay showing the FOXC1 levels in SK-N-BE(2) (G) and SH-SY5Y (H) cells treated with TMG (G, 10 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>) or OSMI-1 (H, 2.0 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>), and those incubated with CHX (20 &#x003bc;g&#x000b7;ml<sup>&#x02212;1</sup>) as indicated. (I) Co-IP and Western blot assays revealing the O-GlcNAcylation of FOXC1 in SH-SY5Y cells stably transfected with mock, Flag-tagged <italic toggle="yes">FOXC1</italic>, and that containing S8A or T68A mutation. (J to L) Dual-luciferase (J), ChIP-qPCR (K, normalized to input, <italic toggle="yes">n</italic> = 3), real-time qRT-PCR (K, normalized to <italic toggle="yes">&#x003b2;-actin</italic>, <italic toggle="yes">n</italic> = 5), and Western blot (L) assays showing the FOXC1 activity, FOXC1 enrichment, and target gene (<italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic>) expression in SH-SY5Y cells stably transfected with mock, Flag-tagged <italic toggle="yes">FOXC1</italic>, and that containing S8A or T68A mutation. (M) Schematic illustration indicating the action modes of OGT-mediated O-GlcNAcylation (G) of FOXC1 in regulating target gene (<italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic>) expression. ANOVA compared the difference in (J). **<italic toggle="yes">P</italic> &#x0003c; 0.01. Data are shown as representative of 3 independent experiments in (A) to (L).</p></caption><graphic xlink:href="research.0703.fig.005" position="float"/></fig></sec><sec id="sec8"><title><italic toggle="yes">EcircOGT</italic>-encoded OGT-570aa inhibits asparagine/alanine biogenesis and ferroptosis repression in NB cells</title><p>To identify the endogenous regulator of OGT activity, considering the roles of circular RNA (circRNA)-generated proteins in regulating the functions of its host gene [<xref rid="B38" ref-type="bibr">38</xref>], we performed the mining of circBase [<xref rid="B39" ref-type="bibr">39</xref>] and open reading frame (ORF) finder (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/orffinder" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/orffinder</ext-link>) databases, which revealed an <italic toggle="yes">OGT</italic>-derived circRNA (<italic toggle="yes">hsa_circ_0091037</italic>, referred to as <italic toggle="yes">ecircOGT</italic>) containing an ORF spanning junction. The precise circularization of <italic toggle="yes">ecircOGT</italic> originating from exons 6 to 20 of <italic toggle="yes">OGT</italic> was confirmed in SH-SY5Y and SK-N-AS cell lines (Fig. <xref rid="F6" ref-type="fig">6</xref>A), showing traits of cytoplasmic abundance and RNase R resistance (Fig. <xref rid="F6" ref-type="fig">6</xref>B). <italic toggle="yes">EcircOGT</italic> was less abundant in NB cell lines or clinical specimens of different International Neuroblastoma Staging System (INSS) stages, in comparison to normal dorsal root ganglia (Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>E and F). Overexpression of <italic toggle="yes">ecircOGT</italic> did not impact the <italic toggle="yes">OGT</italic> expression in NB cells (Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>G). Meanwhile, eukaryotic translation initiation factor 4A3 (EIF4A3), a crucial controller of circRNA biogenesis [<xref rid="B40" ref-type="bibr">40</xref>], was elevated in NB cell lines and tissues (Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>F). In line with data from the ENCORI database (<ext-link xlink:href="https://rnasysu.com/encori/" ext-link-type="uri">https://rnasysu.com/encori/</ext-link>), RNA immunoprecipitation (RIP) test showed EIF4A3 enrichment near exons 6 and 20 of <italic toggle="yes">OGT</italic>, which was reduced by <italic toggle="yes">EIF4A3</italic> knockdown (Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>H). Of note, suppressing <italic toggle="yes">EIF4A3</italic> expression led to higher <italic toggle="yes">ecircOGT</italic> levels in NB cells, without affecting <italic toggle="yes">OGT</italic> expression (Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>I). The expression of a protein with 570 amino acid residues (OGT-570aa), containing a partial TPR domain (382 to 473 aa) of OGT along with 3 extra residues (CHP), was detected in the IMR-32 cell line receiving transfection with FLAG-tagged <italic toggle="yes">ecircOGT</italic>, but was not found in that with mutation of circularization site or ORF (Fig. <xref rid="F6" ref-type="fig">6</xref>C). The protein was mainly located in the nucleus (Fig. <xref rid="F6" ref-type="fig">6</xref>D and E). The asparagine and alanine levels, GSH/GSSG ratio, and NADPH/NADP<sup>+</sup> ratio were decreased, while free liable iron and lipid ROS levels were increased, and the mitochondrial membrane potential and viabilities of IMR-32 cell line were reduced by transfection of <italic toggle="yes">ecircOGT</italic> or its linear ORF, but not by that containing mutation of circularization site (<italic toggle="yes">circOGT1</italic> Mut, Fig. <xref rid="F6" ref-type="fig">6</xref>F to L). These results indicated that <italic toggle="yes">ecircOGT</italic>-encoded OGT-570aa repressed asparagine/alanine biogenesis and ferroptosis repression in NB cells.</p><fig position="float" id="F6"><label>Fig. 6.</label><caption><p><italic toggle="yes">EcircOGT</italic>-encoded OGT-570aa inhibits asparagine/alanine biogenesis and ferroptosis repression of NB cells. (A) Validation of <italic toggle="yes">ecircOGT</italic> in cDNA or genomic DNA (gDNA) using convergent or divergent primers (top panel) and Sanger sequencing (bottom panel). (B) RNA-FISH (left panel) assay showing cytoplasmic and nuclear localization of <italic toggle="yes">ecircOGT</italic> in cultured SH-SY5Y cells using a junction-specific antisense probe (red), with nuclei staining with DAPI (blue). Sense probe with RNase R (3 U&#x000b7;mg<sup>&#x02212;1</sup>) treatment was used as a negative control. The <italic toggle="yes">GAPDH</italic> and <italic toggle="yes">U1</italic> were applied as positive controls. Scale bar: 10 &#x003bc;m. Real-time qRT-PCR (right panel, normalized to <italic toggle="yes">&#x003b2;-actin</italic>) assay indicating the distribution of <italic toggle="yes">ecircOGT</italic> in cytoplasmic and nuclear fractions of SH-SY5Y cells (<italic toggle="yes">n</italic> = 4). (C) Schematic illustration (left panel) and Western blot (right panel) assay showing the expression of <italic toggle="yes">ecircOGT</italic>-encoded protein (OGT-570aa) in IMR-32 cells transfected with empty vector (mock), 3&#x000d7;Flag-tagged <italic toggle="yes">ecircOGT</italic>, or 3&#x000d7;Flag-tagged <italic toggle="yes">ecircOGT</italic> with circularization site or ORF mutation (Mut). (D) Immunofluorescence assay revealing nuclear colocalization of OGT-570aa in SH-SY5Y cells, with nuclei stained by DAPI (blue). Scale bar: 10 &#x003bc;m. (E) Western blot assay revealing the levels of OGT-570aa in cytoplasmic and nuclear fractions of IMR-32 cells stably transfected with mock or 3&#x000d7;Flag-tagged <italic toggle="yes">ecircOGT</italic>. (F to H) Relative asparagine and alanine levels (F), GSH/GSSG ratio (G), and NADPH/NADP<sup>+</sup> ratio (H) in IMR-32 cells stably transfected with mock, <italic toggle="yes">ecircOGT</italic>, linear p570 construct, or <italic toggle="yes">ecircOGT</italic> with circularization site mutation (<italic toggle="yes">ecircOGT</italic> Mut, <italic toggle="yes">n</italic> = 3). (I) Representative images (left panel) and quantification (right panel) of RhoNox-1 staining in IMR-32 cells stably transfected with mock, <italic toggle="yes">ecircOGT</italic>, linear p570 construct, or <italic toggle="yes">ecircOGT</italic> Mut (<italic toggle="yes">n</italic> = 3). Scale bars: 10 &#x003bc;m. (J) Flow cytometry showing the lipid ROS levels in IMR-32 cells stably transfected with mock, <italic toggle="yes">ecircOGT</italic>, linear p570 construct, or <italic toggle="yes">ecircOGT</italic> Mut (<italic toggle="yes">n</italic> = 3). (K) Representative images (left panel) and quantification (right panel) of JC-1 (2&#x02009;&#x003bc;g&#x000b7;ml<sup>&#x02212;1</sup>) staining in IMR-32 cells stably transfected with mock, <italic toggle="yes">ecircOGT</italic>, linear p570 construct, or <italic toggle="yes">ecircOGT</italic> Mut (<italic toggle="yes">n</italic> = 3). (L) MTT colorimetric assay indicating the viabilities of IMR-32 cells stably transfected with mock, <italic toggle="yes">ecircOGT</italic>, linear p570 construct, or <italic toggle="yes">ecircOGT</italic> Mut (<italic toggle="yes">n</italic> = 3). ANOVA compared the difference in (F) to (I), (K) and (J). **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (A) to (L).</p></caption><graphic xlink:href="research.0703.fig.006" position="float"/></fig></sec><sec id="sec9"><title>OGT-570aa inhibits ferroptosis repression and NB progression via blocking OGT&#x02013;FOXC1 interaction</title><p>Since the above evidence revealed that OGT-570aa contained partial TPR domain essential for binding of OGT to FOXC1, we further investigated the hypothesis that it might influence the OGT&#x02013;FOXC1 interaction (Fig. <xref rid="F7" ref-type="fig">7</xref>A). Ectopic expression of <italic toggle="yes">ecircOGT</italic>, but not of <italic toggle="yes">ecircOGT</italic> Mut, increased the binding of OGT-570aa with FOXC1, leading to reduced OGT&#x02013;FOXC1 interaction in IMR-32 cells (Fig. <xref rid="F7" ref-type="fig">7</xref>B). Of note, stable overexpression of <italic toggle="yes">ecircOGT</italic> decreased FOXC1 activity (Fig. <xref rid="F7" ref-type="fig">7</xref>C) and reduced FOXC1 enrichment and transcript or protein levels of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in IMR-32 cells, along with a decrease in CBS and FTH1 expression (Fig. <xref rid="F7" ref-type="fig">7</xref>D and E), which were rescued by ectopic expression of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="F7" ref-type="fig">7</xref>C to E). In addition, transfection of <italic toggle="yes">FOXC1</italic> prevented the reduction in asparagine and alanine levels, GSH/GSSG ratio, GPX4 activity, or NADPH/NADP<sup>+</sup> ratio; an increase in free liable iron, lipid ROS levels, and mitochondria; and a decrease in growth and invasiveness of IMR-32 cells exhibiting stable <italic toggle="yes">ecircOGT</italic> overexpression (Fig. <xref rid="F7" ref-type="fig">7</xref>F to N and Fig. <xref rid="supplementary-material-1" ref-type="sec">S7</xref>J). Together, these results showed that OGT-570aa repressed ferroptosis repression and aggressiveness of NB cells via blocking OGT&#x02013;FOXC1 interaction.</p><fig position="float" id="F7"><label>Fig. 7.</label><caption><p>OGT-570aa inhibits ferroptosis repression and NB progression via blocking OGT&#x02013;FOXC1 interaction. (A) Schematic illustration indicating the action modes of <italic toggle="yes">ecircOGT</italic>-encoded p570 in regulating OGT&#x02013;FOXC1 interaction and FOXC1 target gene (<italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic>) expression. (B) Co-IP and Western blot assays showing the interaction among OGT-570aa, OGT, and FOXC1 in IMR-32 cells stably transfected with empty vector (mock), <italic toggle="yes">ecircOGT</italic>, or <italic toggle="yes">ecircOGT</italic> Mut. (C to E) Dual-luciferase (C), ChIP and qPCR (D, normalized to input), real-time qRT-PCR (D, normalized to <italic toggle="yes">&#x003b2;-actin</italic>), and Western blot (E) assays showing the FOXC1 activity, FOXC1 enrichment, and downstream gene (<italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, and <italic toggle="yes">FTH1</italic>) expression in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT</italic>. (F to I) Relative asparagine and alanine levels (F), GSH/GSSG ratio (G), GPX4 activity (H), and NADPH/NADP<sup>+</sup> ratio (I) in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT</italic> (<italic toggle="yes">n</italic> = 3). (J) Representative images (left panel) and quantification (right panel) of RhoNox-1 staining in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT</italic> (<italic toggle="yes">n</italic> = 3). Scale bars: 10 &#x003bc;m. (K) Flow cytometry showing the lipid ROS levels in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT</italic> (<italic toggle="yes">n</italic> = 3). (L) Representative images of mitochondria shrunk in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT.</italic> Scale bars: 0.5 &#x003bc;m. (M) and (N) Representative images (left panel) and quantification (right panel) of soft agar (M) and matrigel invasion (N) in IMR-32 cells stably transfected with mock, <italic toggle="yes">FOXC1</italic>, or <italic toggle="yes">ecircOGT</italic> (<italic toggle="yes">n</italic> = 3). ANOVA compared the difference in (C), (F) to (I), (J), (M), and (N). **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (B) to (N).</p></caption><graphic xlink:href="research.0703.fig.007" position="float"/></fig></sec><sec id="sec10"><title>MN suppresses NB progression via facilitating OGT-570aa&#x02013;FOXC1 interaction</title><p>To screen chemical inhibitor of FOXC1 activity, NB cells were treated with 1,495 Food and Drug Administration (FDA)-approved drugs (Fig. <xref rid="F8" ref-type="fig">8</xref>A), while 159 compounds with inhibition ratios of more than 80% on cellular viabilities were obtained (Fig. <xref rid="F8" ref-type="fig">8</xref>B), which were subjected to dual-luciferase assay for observing their effects on FOXC1 activity. The results indicated that 17 chemicals were able to suppress FOXC1 activity with efficiency larger than 80% (Fig. <xref rid="F8" ref-type="fig">8</xref>C). Among them, canagliflozin, dasatinib, indacaterol, menadione, MN, paroxetine HCl, proguanil, trifluoperazine, tegaserod maleate, and vortioxetine suppressed the OGT&#x02013;FOXC1 interaction in BiFC assay, with MN ranking first in inhibitory effects (Fig. <xref rid="supplementary-material-1" ref-type="sec">S8</xref>A). Notably, the viabilities of HEK293 cells were not impacted by MN (Fig. <xref rid="supplementary-material-1" ref-type="sec">S8</xref>B). In co-IP and Western blot experiments, MN substantially facilitated the binding of OGT-570aa to FOXC1, resulting in a decrease of OGT&#x02013;FOXC1 interaction and the down-regulation of FOXC1 (Fig. <xref rid="F8" ref-type="fig">8</xref>D). The use of ferrite-glycidyl methacrylate (FG) beads [<xref rid="B41" ref-type="bibr">41</xref>] in affinity purification showed a specific interaction of MN with recombinant OGT-570aa, but not with OGT or FOXC1 protein (Fig. <xref rid="F8" ref-type="fig">8</xref>E and F). Molecular docking via the HDOCK program (<ext-link xlink:href="http://hdock.phys.hust.edu.cn/" ext-link-type="uri">http://hdock.phys.hust.edu.cn/</ext-link>) revealed direct interaction (distance, 3.3 &#x000c5;) of MN with the 468th to 470th residues (GLY) of OGT-570aa (Fig. <xref rid="F8" ref-type="fig">8</xref>G), which was further validated by differential scanning fluorimetry (DSF) assay (Fig. <xref rid="F8" ref-type="fig">8</xref>H and I). The activity and enrichment of FOXC1 were decreased in NB cells treated with MN, leading to lower transcript and protein levels of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic>. This was accompanied by down-regulation of CBS and FTH1, but ectopic expression of <italic toggle="yes">FOXC1</italic> prevented these effects (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>A to C). Administration of MN reduced asparagine and alanine levels (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>D), GSH/GSSG ratio (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>E), or NADPH/NADP<sup>+</sup> ratio (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>F); increased the free liable iron and lipid ROS levels (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>G and H); and attenuated the mitochondrial membrane potential (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>I), while excessive <italic toggle="yes">FOXC1</italic> expression reversed these effects (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>D to I). The proliferative and invasive capabilities of NB cell lines were hindered by treatment with MN, but this effect was reversed by the ectopic expression of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="supplementary-material-1" ref-type="sec">S9</xref>J and K). In nude mice, administration of MN decreased the growth, mass, target gene expression, Ki-67 or CD31 levels, and asparagine and alanine levels of hypodermic xenograft tumors (Fig. <xref rid="F8" ref-type="fig">8</xref>J and Fig. <xref rid="supplementary-material-1" ref-type="sec">S10</xref>A to D). Athymic nude mice receiving MN injection via the tail vein showed a lower number of lung metastatic colonies and increased survival rate in the experimental metastasis assay (Fig. <xref rid="F8" ref-type="fig">8</xref>J and Fig. <xref rid="supplementary-material-1" ref-type="sec">S10</xref>E).</p><fig position="float" id="F8"><label>Fig. 8.</label><caption><p>Miconazole nitrate (MN) suppresses NB progression via facilitating OGT-570aa&#x02013;FOXC1 interaction. (A) Schematic illustration indicating the screening of FOXC1 inhibitor from 1,495 FDA-approved drugs by MTT colorimetric, dual-luciferase, and BiFC assays. (B) MTT colorimetric assay showing the viabilities of SH-SY5Y and SK-N-BE(2) cells treated with 159 compounds. (C) Dual-luciferase assay revealing the FOXC1 activity in SK-N-BE(2) cells treated with 1,495 FDA-approved drugs, with 16 of them possessing inhibitory ratios larger than 50%. (D) Co-IP and Western blot assays showing the interaction among OGT-570aa, OGT, and FOXC1 in SK-N-BE(2) cells treated with solvent or MN. (E and F) Silver staining (E) and Western blot (F) assays indicating recombinant proteins with affinity to FG beads covalently conjugated with MN (20 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>). (G) Molecular docking analysis of OGT-570aa and MN via the HDOCK program (<ext-link xlink:href="http://hdock.phys" ext-link-type="uri">http://hdock.phys</ext-link>.hust.edu.cn/). (H and I) DSF assay (H) and temperature (I) showing the fluorescence intensity in HEPES, solvent (DMSO), MN, OGT-570aa, or FOXC1. (J) Growth curve, weight at the end points of xenograft tumors, lung metastatic counts, and Kaplan&#x02013;Meier curves of nude mice treated with subcutaneous or tail vein injection of SK-N-BE(2) cells, and treated with DMSO or MN (50 mg&#x000b7;kg<sup>&#x02212;1</sup>, <italic toggle="yes">n</italic> = 5 for each group). (K) Schematic depicting the mechanisms underlying OGT-570aa/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic>-regulated tumor progression: as a transcription factor, FOXC1 facilitates the expression of asparagine/alanine biogenesis genes (<italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic>), while OGT interacts with FOXC1 to facilitate its O-GlcNAcylation and stability, resulting in increase of asparagine or alanine, and up-regulation of CBS and FTH1 essential for ferroptosis resistance. Meanwhile, as an EIF4A3-repressed circRNA derived from <italic toggle="yes">OGT</italic>, <italic toggle="yes">ecircOGT</italic> is able to encode a novel protein (OGT-570aa) containing a partial TPR domain of OGT protein, which competitively binds with FOXC1 and blocks OGT&#x02013;FOXC1 interaction. Administration of MN facilitates the binding of OGT-570aa to FOXC1, resulting in repression of <italic toggle="yes">ASNS</italic> or <italic toggle="yes">GPT2</italic> expression, ferroptosis resistance, tumorigenesis, and aggressiveness. Student&#x02019;s <italic toggle="yes">t</italic> test or ANOVA compared the difference in (I) and (J). Log-rank test for survival comparison in (J). **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001. NS, nonsignificant. Data are shown as mean&#x02009;&#x000b1;&#x02009;SEM (error bars) or representative of 3 independent experiments in (D) to (J).</p></caption><graphic xlink:href="research.0703.fig.008" position="float"/></fig><p>Higher levels of <italic toggle="yes">OGT</italic>, <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, and <italic toggle="yes">FTH1</italic>, as well as lower expression of <italic toggle="yes">ecircOGT</italic> or OGT-570aa, were noted in NB samples from patients with advanced INSS stages (Fig. <xref rid="supplementary-material-1" ref-type="sec">S11</xref>A and B). In Kaplan&#x02013;Meier survival assay, elevated <italic toggle="yes">OGT</italic> (<italic toggle="yes">P</italic> = 2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;2</sup> and <italic toggle="yes">P</italic> = 1.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;3</sup>), <italic toggle="yes">FOXC1</italic> (<italic toggle="yes">P</italic> = 2.2&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;14</sup> and <italic toggle="yes">P</italic> = 4.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;2</sup>), <italic toggle="yes">ASNS</italic> (<italic toggle="yes">P</italic> = 2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;7</sup> and <italic toggle="yes">P</italic> = 8.3&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;3</sup>), <italic toggle="yes">GPT2</italic> (<italic toggle="yes">P</italic> = 1.4&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;15</sup> and <italic toggle="yes">P</italic> = 1.6&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;9</sup>), <italic toggle="yes">CBS</italic> (<italic toggle="yes">P</italic> = 1.5&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;16</sup> and <italic toggle="yes">P</italic> = 1.1&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>), and <italic toggle="yes">FTH1</italic> (<italic toggle="yes">P</italic> = 2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;4</sup> and <italic toggle="yes">P</italic> = 1.5&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;2</sup>) were associated with poorer prognosis in 498 (GSE62564) and 283 (GSE85047) NB cases (Fig. <xref rid="supplementary-material-1" ref-type="sec">S11</xref>C). In 498 (GSE62564) NB specimens, the <italic toggle="yes">ASNS</italic> (<italic toggle="yes">R</italic> = 0.124, <italic toggle="yes">P</italic> = 5.5&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;3</sup>) or <italic toggle="yes">GPT2</italic> (<italic toggle="yes">R</italic> = 0.189, <italic toggle="yes">P</italic> = 2.1&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>) levels were substantially correlated with those of <italic toggle="yes">FOXC1</italic> (Fig. <xref rid="supplementary-material-1" ref-type="sec">S11</xref>D). In addition, higher expression of <italic toggle="yes">OGT</italic>, <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">ASNS</italic>, <italic toggle="yes">GPT2</italic>, <italic toggle="yes">CBS</italic>, or <italic toggle="yes">FTH1</italic> was also associated with poorer outcomes in clinical cases with renal clear cell carcinoma or glioma (Fig. <xref rid="supplementary-material-1" ref-type="sec">S12</xref>). These findings suggested that MN inhibited tumor progression by promoting the interaction between OGT-570aa and FOXC1.</p></sec></sec><sec id="sec11"><title>Discussion</title><p>Asparagine, a nonessential amino acid, is de novo synthesized through the transfer of an acylamino group from glutamine to aspirate, a process mediated by ASNS [<xref rid="B29" ref-type="bibr">29</xref>], and is required for protein or nucleotide synthesis [<xref rid="B29" ref-type="bibr">29</xref>]. Increased <italic toggle="yes">ASNS</italic> expression is linked to unfavorable outcome in multiple solid malignancies, including prostate cancer [<xref rid="B42" ref-type="bibr">42</xref>], HCC [<xref rid="B43" ref-type="bibr">43</xref>], and glioma [<xref rid="B44" ref-type="bibr">44</xref>]. Ectopic expression of <italic toggle="yes">ASNS</italic> rescues the apoptosis and cell cycle arrest induced by activating transcription factor 4 deficiency or nutrition stress [<xref rid="B45" ref-type="bibr">45</xref>]. Meanwhile, knockdown of <italic toggle="yes">ASNS</italic> reduces <italic toggle="yes">MYC</italic> expression and tumor growth [<xref rid="B46" ref-type="bibr">46</xref>], implicating <italic toggle="yes">ASNS</italic> as a possible focus for cancer treatment. GPT2 is a mitochondrial aminotransferase catalyzing the reversible reaction between pyruvate and glutamate to produce alanine and &#x003b1;-ketoglutarate [<xref rid="B30" ref-type="bibr">30</xref>]. In breast cancer, <italic toggle="yes">GPT2</italic> serves as a pivot between glycolysis and glutaminolysis, and promotes tumorigenesis and stemness [<xref rid="B47" ref-type="bibr">47</xref>]. Meanwhile, silencing of <italic toggle="yes">GPT2</italic> is able to suppress the proliferation of signet ring cell carcinoma [<xref rid="B48" ref-type="bibr">48</xref>] or pancreatic cancer [<xref rid="B49" ref-type="bibr">49</xref>], corroborating GPT2 as a critical enzyme in oncogenesis. In this research, we discovered that FOXC1 drove the transcription of genes (<italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic>) crucial for amino acid metabolism, and facilitated the production of asparagine and alanine, resulting in increase of CBS and FTH1 protein synthesis, ferroptosis resistance, tumorigenesis, and aggressiveness of NB. Furthermore, OGT directly interacted with FOXC1 to block its proteasomal degradation via mediating O-GlcNAcylation. Meanwhile, a novel OGT-570aa isoform encoded by <italic toggle="yes">ecircOGT</italic> was able to inhibit the interaction of OGT and FOXC1, thus promoting ferroptosis and decreasing tumorigenesis and aggressiveness (Fig. <xref rid="F8" ref-type="fig">8</xref>K), which suggests that targeting the <italic toggle="yes">ecircOGT</italic>/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic> axis could be an option for NB treatment.</p><p>OGT is a nutrient- or stress-responsive glycosyltransferase catalyzing the incorporation of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to serine or threonine residues [<xref rid="B50" ref-type="bibr">50</xref>], and regulates the structure, stability, or function of nuclear and cytoplasmic proteins, such as kinases, phosphatases, transcription factors, and metabolic enzymes [<xref rid="B50" ref-type="bibr">50</xref>]. Recent studies reveal that OGT-mediated O-GlcNAcylation regulates multiple phenotypes of tumorigenesis [<xref rid="B51" ref-type="bibr">51</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>]. For example, the nuclear localization of serine/arginine-rich protein kinase 2 (SRPK2) is influenced by O-GlcNAcylation, promoting both de novo lipogenesis and tumorigenesis [<xref rid="B51" ref-type="bibr">51</xref>]. Glucose-triggered O-GlcNAcylation of phosphoribosyl pyrophosphate synthetase 1 (PRPS1) boosts generation of nucleotide and nicotinamide adenine dinucleotide (NAD) crucial for tumor growth [<xref rid="B52" ref-type="bibr">52</xref>]. O-GlcNAcylation of yes-associated protein (YAP) represses its interaction with large tumor suppressor gene 1 (LATS1), resulting in its transactivation and tumor progression [<xref rid="B53" ref-type="bibr">53</xref>]. In addition, O-GlcNAcylation stabilizes Sirtuin 7 by inhibiting its interaction with proteasome activator subunit 3, and promotes pancreatic cancer progression [<xref rid="B54" ref-type="bibr">54</xref>]. In this study, we found that OGT interacted with FOXC1 to mediate its O-GlcNAcylation, leading to its up-regulation in driving transcription of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic> in NB cells. Structurally, FOXC1 protein contains an N-terminal activation domain (AD) [<xref rid="B16" ref-type="bibr">16</xref>]. Our data indicated that TPR domain of OGT was able to interact with AD1 of FOXC1, while their underlying structures warrant further investigation.</p><p>CircRNAs are loops of single-stranded noncoding RNAs formed through back splicing [<xref rid="B38" ref-type="bibr">38</xref>]. EIF4A3, the core element of exon junction complex, is able to facilitate or repress the biogenesis of circRNAs [<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>]. For example, EIF4A3 promotes the circularization of <italic toggle="yes">circIKBKB</italic> [<xref rid="B55" ref-type="bibr">55</xref>], while it inhibits the expression of <italic toggle="yes">circ_0087429</italic> by binding to flanking regions [<xref rid="B56" ref-type="bibr">56</xref>]. In this study, we discovered that <italic toggle="yes">ecircOGT</italic> was a circRNA repressed by EIF4A3, but it did not alter the levels of parental gene <italic toggle="yes">OGT</italic> in NB. Recent studies show that circRNAs are crucial in the development and progression of cancer through sponging microRNAs or binding with RNA-binding proteins [<xref rid="B38" ref-type="bibr">38</xref>]. Some circRNAs like <italic toggle="yes">circ-ZNF609</italic>, <italic toggle="yes">circFBXW7</italic>, <italic toggle="yes">circMbl</italic>, and <italic toggle="yes">circ-SHPRH</italic> have the ability to produce peptides or proteins through internal ribosome entry site or N6-methyladenosine (m<sup>6</sup>A) modification [<xref rid="B38" ref-type="bibr">38</xref>]. For example, m<sup>6</sup>A modification facilitates the production of circMAP3K4-455aa in HCC, which protects cancer cells from cisplatin treatment and predicts worse prognosis of patients [<xref rid="B57" ref-type="bibr">57</xref>]. <italic toggle="yes">CircCAPG</italic> produces a new protein CAPG-171aa that boosts the growth and spread of triple-negative breast carcinoma [<xref rid="B58" ref-type="bibr">58</xref>]. <italic toggle="yes">CircPPP1R12A</italic> produces a protein that enhances colon cancer growth and spread by activation of the Hippo-YAP signaling pathway [<xref rid="B59" ref-type="bibr">59</xref>]. Meanwhile, <italic toggle="yes">circZKSCAN1</italic>-encoded peptide serves as a tumor suppressor and sensitizes HCC cells to sorafenib via ubiquitination of mammalian target of rapamycin [<xref rid="B60" ref-type="bibr">60</xref>]. In the current study, we found that <italic toggle="yes">ecircOGT</italic>-encoded OGT-570aa contained a partial TPR domain of OGT protein, which was efficient in promoting ferroptosis and decreasing tumor progression by competitively binding with FOXC1 and reducing interaction of OGT with FOXC1, indicating its importance as a therapeutic focus regulating ferroptosis and tumor progression.</p><p>MN is a broad-spectrum imidazole antifungal agent [<xref rid="B61" ref-type="bibr">61</xref>] and is able to suppress neuroinflammation [<xref rid="B62" ref-type="bibr">62</xref>]. Preliminary evidences indicate that MN also exerts anticancer effects in various solid tumors [<xref rid="B63" ref-type="bibr">63</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>]. MN induces cell cycle arrest [<xref rid="B63" ref-type="bibr">63</xref>] and triggers apoptosis of bladder or colon cancer via the death receptor 5-dependent or mitochondrial-mediated pathway [<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>]. MN suppresses the production of vascular endothelial growth factor in gliomas or breast cancer by blocking the translation of hypoxia inducible factor 1 alpha [<xref rid="B65" ref-type="bibr">65</xref>]. Moreover, MN reduces global protein production by causing phosphorylation of translation initiation factor 2 alpha [<xref rid="B65" ref-type="bibr">65</xref>]. In osteosarcoma cells, MN represses the proliferation of tumor cells by increasing Ca<sup>2+</sup> levels [<xref rid="B66" ref-type="bibr">66</xref>]. However, the anticancer mechanisms of MN are not well understood. In this research, we found that MN could facilitate the binding of OGT-570aa to FOXC1, thus reducing the biogenesis of alanine and asparagine, inducing ferroptosis, and inhibiting tumorigenesis and aggressiveness, which indicates its potential application as an inhibitor of tumor progression.</p><p>In summary, we show that enhanced FOXC1 levels are linked to a poor outcome for NB patients. FOXC1 is stabilized by OGT-mediated O-GlcNAcylation in liquid condensates to serve as a transcriptional activator of <italic toggle="yes">ASNS</italic> and <italic toggle="yes">GPT2</italic>, thereby increasing intracellular asparagine and alanine biogenesis, which enhances the ability of NB cells to resist ferroptosis, as well as promotes their growth, invasion, and metastasis. Meanwhile, <italic toggle="yes">ecircOGT</italic>, an EIF4A3-inhibited circRNA originating from <italic toggle="yes">OGT</italic>, can produce a new protein termed as OGT-570aa, which inhibits the interaction of OGT with FOXC1. Administration of MN facilitates the interaction of OGT-570aa with FOXC1, thus suppressing tumorigenesis and aggressiveness. We believe that this work reveals the crucial roles and mechanisms of <italic toggle="yes">ecircOGT</italic>/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic> axis in regulating ferroptosis, and provides new therapeutic strategies for tumors. More efforts are needed to reveal the additional functions and target genes of <italic toggle="yes">FOXC1</italic> during the progression of NB and other tumors. The prognostic values of the <italic toggle="yes">ecircOGT</italic>/<italic toggle="yes">OGT</italic>/<italic toggle="yes">FOXC1</italic> axis and downstream genes for NB warrant further investigation via using a larger series of cases with longer follow-up duration.</p></sec><sec id="sec12"><title>Materials and Methods</title><sec id="sec13"><title>Culture of cell lines</title><p>The cell lines of NB [SK-N-DZ (CRL-2149), IMR-32 (CCL-127), SK-N-BE(2) (CRL-2271), SK-N-AS (CRL-2137), SH-SY5Y (CRL-2266), and SK-N-SH (HTB-11)], prostate cancer (PC-3, CRL-1435), cervical cancer (HeLa, CCL-2), and embryonic kidney (HEK293, CRL-1573) were acquired from the American Type Culture Collection (Rockville, MD) or the Pediatric Oncology Group Cell Bank (Lubbock, TX). Short tandem repeat analysis was used for verification of cell lines, which were used within 6 months. Regularly, the Mycoplasma PCR Detection Kit (ab289834, Abcam Inc., Cambridge, MA) was used to monitor mycoplasma contamination. The SK-N-DZ, IMR-32, SK-N-AS, SK-N-SH, HeLa, and HEK293 cells were cultured with Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) (Invitrogen, Carlsbad, CA), while SK-N-BE(2) and SH-SY5Y cells were respectively grown in Minimum Essential Medium (MEM)/F12 or DMEM/F12 (Invitrogen) along with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO). The PC-3 cells were grown in RPMI-1640 medium (Invitrogen) containing 10% FBS. Cells were exposed to EBSS (Sigma), erastin (MedChemExpress, Monmouth Junction, NJ), rapamycin (MedChemExpress), cisplatin (MedChemExpress), elesclomol (MedChemExpress), AOAA (MedChemExpress), D3-3 (MedChemExpress), 1,6-Hex (Sigma), MG132 (Sigma), Thiamet-G (TMG, Sigma), OSMI-1 (Sigma), or MN (MedChemExpress) at 37 &#x000b0;C in 5% CO<sub>2</sub>. Amino acid deprivation or supplement was achieved by formulating medium, according to manuals of manufacturers (Life Technologies Inc.).</p></sec><sec id="sec14"><title>Real-time quantitative RT-PCR</title><p>RNAs from the entire cell, cytoplasm, or nucleus were obtained through the use of the PureLink RNA Mini Kit (Thermo Fisher Scientific Inc., Waltham, MA) or Cytoplasmic and Nuclear RNA Purification Kit (Norgen Biotek, Ontario, Canada). To detect circRNA, samples were digested by RNase R (3 U&#x000b7;&#x003bc;g<sup>&#x02212;1</sup>, Abcam Inc.) for 15 min at 37 &#x000b0;C, followed by cDNA synthesis using a Reverse Transcription kit (QIAGEN, Germantown, MD). The SYBR Green Master Mix from Bio-Rad (Hercules, CA) and primers (Table <xref rid="supplementary-material-1" ref-type="sec">S5</xref>) were utilized for mRNA and circRNA quantification [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec15"><title>RNA fluorescence in&#x000a0;situ hybridization</title><p>Tsingke Biotech Co., Ltd (Beijing, China) synthesized biotin-labeled antisense or sense probes (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) targeting <italic toggle="yes">ecircOGT</italic> junction. The probes for glyceraldehyde 3-phosphate dehydrogenase (<italic toggle="yes">GAPDH</italic>) or U1 small nuclear 1 (<italic toggle="yes">U1</italic>) were created via the HighFidelity Digoxigenin PCR Labeling Kit from Jena Bioscience (Jena, Germany) and PCR products (Table <xref rid="supplementary-material-1" ref-type="sec">S5</xref>). Cells were treated with probe (40 nmol&#x000b7;l<sup>&#x02212;1</sup>) and incubated at 37 &#x000b0;C for 16 h, with or without RNase R (3 U&#x000b7;&#x003bc;g<sup>&#x02212;1</sup>) treatment. The Ribo fluorescence in&#x000a0;situ hybridization (FISH) Kit (RiboBio, Guangzhou, China) was employed to detect <italic toggle="yes">ecircOGT</italic>, while nuclei were stained by 4&#x02032;,6-diamidino-2-phenylindole (DAPI) from Sigma [<xref rid="B68" ref-type="bibr">68</xref>,<xref rid="B69" ref-type="bibr">69</xref>].</p></sec><sec id="sec16"><title>Western blot</title><p>Proteins were isolated by cell lysis buffer from Cell Signaling Technology Inc. (Danvers, MA). The Nuclear/Cytosol Fractionation kit (ab289882) was employed for segregating cytoplasmic or nuclear parts. Western blot procedure was carried out as previously explained [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>], using antibodies designed specifically for FOXC1 (ab226219), OGT (ab177941), ASNS (ab126254), GPT2 (ab232963), CBS (ab96252), FTH1 (ab75972), DCUN1D1 (ab181233), RBX1 (ab133565), Myc-tag (ab9106), GST-tag (ab111947), &#x003b2;-actin (ab6276, Abcam Inc.), GAPDH (2118), histone H3 (9715), MBP-tag (2396), Flag-tag (2368), His-tag (2365), or HA-tag (2367, Cell Signaling Technology Inc., Danvers, MA). A polyclonal antibody of OGT-570aa was created by vaccinating rabbits with a synthetic peptide matching the C-terminal end of OGT-570aa (LWAGTPMVTMPGCHP) at ABclonal Biotechnology Co., Ltd in Wuhan, China.</p></sec><sec id="sec17"><title>Ectopic expression or silencing of genes</title><p>Genechem Co., Ltd (Shanghai, China) supplied human <italic toggle="yes">FOXC1</italic> cDNA (1,662 bp) and <italic toggle="yes">OGT</italic> cDNA (3,131 bp), which were then inserted into CV186. The PCR primers (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) were used to amplify their truncations, which were then inserted into various plasmids including pCMV-3Tag-1A, pMAL-c4X, pCMV-HA, pGEX-6P-1, pET28a-EGFP, pET28a-mCherry, and pmCherry-N1 from Addgene and Genprice Inc. The linear form of <italic toggle="yes">ecircOGT</italic> (<italic toggle="yes">hsa_circ_0091037</italic>) was amplified from NB specimens using specific primer sets (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) and then inserted into pLCDH-ciR (Geneseed Biotech Co., Guangzhou, China). A construction of <italic toggle="yes">ecircOGT</italic>-3Flag was made by adding a 3&#x000d7;Flag-coding gene before the stop codon in linear <italic toggle="yes">ecircOGT</italic> (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>). The OGT-570aa-3Flag sequence (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) was inserted into pcDNA3.1-mini or pGEX-6P-1 (Addgene) through subcloning. The QuikChange II Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) was used along with primers (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) to induce mutations in <italic toggle="yes">FOXC1</italic>, <italic toggle="yes">OGT</italic>, or ecircOGT constructs. Specific oligonucleotides targeting shRNAs (Table <xref rid="supplementary-material-1" ref-type="sec">S7</xref>) were inserted into GV298 (Genechem Co., Ltd).</p></sec><sec id="sec18"><title>Lentiviral packaging</title><p>The HEK293T cells were co-transfected by psPAX2 and pMD2G (Addgene) along with lentiviral vectors. Infectious lentivirus was extracted at 36 and 60 h posttransfection, filtered through 0.45-&#x003bc;m polyvinylidene difluoride filters (Sigma), and then diluted in phosphate-buffered saline (PBS).</p></sec><sec id="sec19"><title>Dual luciferase reporter assay</title><p>A luciferase reporter of human FOXC1 activity was created by inserting oligonucleotides with 4 standard FOXC1 motifs (Table <xref rid="supplementary-material-1" ref-type="sec">S6</xref>) into pGL4.1 vector (Promega, Madison, WI). The dual-luciferase assay was conducted using a GloMax Luminometer (Promega) [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec20"><title>ChIP analysis</title><p>ChIP experiment was undertaken with the EZ-ChIP kit from MerckMillipore (Darmstadt, Germany) and antibodies targeting FOXC1 (PA1-807, Thermo Fisher Scientific Inc.). DNA fragments with a mean size of 200 bp were generated using sonication. The SYBR Green Master Mix from Bio-Rad and the primers listed in Table <xref rid="supplementary-material-1" ref-type="sec">S5</xref> were utilized for conducting real-time quantitative PCR [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec21"><title>RNA-seq and polysome profiling</title><p>The TRIzol reagent (Invitrogen) was used to extract total RNA from 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> tumor cells. To conduct polysome profiling, a sucrose density gradient of 15% to 45% (w/v) was newly made in an SW41 ultracentrifuge tube from Beckman (Indianapolis, IN). Cells were broken down in a solution containing polysome lysis buffer (100 mmol&#x000b7;l<sup>&#x02212;1</sup> KCl, 100 mg&#x000b7;ml<sup>&#x02212;1</sup> CHX, 2% Triton X-100, 5 mmol&#x000b7;l<sup>&#x02212;1</sup> MgCl<sub>2</sub>, and 10 mmol&#x000b7;l<sup>&#x02212;1</sup> HEPES, pH 7.4), and then placed on sucrose gradients for centrifugation at 36,000 &#x000d7; <italic toggle="yes">g</italic> for 2 h. A portion of each ribosome fraction was used to isolate total RNA using TRIzol reagent. Library creation and transcriptome sequencing were carried out using the Illumina HiSeq X Ten platform by Wuhan SeqHealth Technology Co., Ltd. (China). With the HTSeq v0.6.0 tool, 100-bp paired-end initial reads were aligned. The data were uploaded to Gene Expression Omnibus (GEO) under the accession numbers GSE294551 and GSE294552.</p></sec><sec id="sec22"><title>Co-IP and proteomics analysis</title><p>The recombinant GST-tagged OGT and MBP-tagged FOXC1 proteins were prepared as previously described [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>]. Preclearing lysates were undertaken by incubating with Protein A/G magnetic beads (HY-K0202, MedChemExpress) along with an isotype control [<xref rid="B71" ref-type="bibr">71</xref>]. Next, co-IP was performed as outlined in previous studies [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>], using antibodies targeted toward FOXC1 (ab226219), OGT (ab177941), GST-tag (ab111947), HA-tag (ab1424), Flag-tag (ab125243, Abcam Inc.), or MBP-tag (66003-1-Ig, Proteintech Group, Inc., Rosemont, IL). The proteins attached to Protein A/G magnetic beads were analyzed using silver staining, Western blotting, and mass spectrometry (SpecAlly Life Technology Co., Ltd, Wuhan, China) [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec23"><title>Immunofluorescence assay</title><p>The cells were placed on coverslips, treated with 4% paraformaldehyde, blocked by 5% milk for 1 h, and exposed to antibodies targeting FOXC1 (ab226219, Abcam Inc. 1:200 dilution), OGT (ab177941, Abcam Inc. 1:200 dilution), or OGT-570aa (ABclonal Biotechnology Co., Ltd, 1:200 dilution) overnight at 4 &#x000b0;C. Next, coverslips were exposed to Alexa Fluor 488-conjugated anti-rabbit IgG (4412) or Alexa Fluor 594-conjugated anti-mouse IgG (8890, Cell Signaling Technology Inc.), followed by DAPI (Sigma) staining. The photos were taken with a scanning confocal microscope from Nikon Instruments Inc, Japan [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec24"><title>BiFC assay</title><p>The cDNA of human <italic toggle="yes">FOXC1</italic> or <italic toggle="yes">OGT</italic> was ligated into either pBiFC-VC155 or pBiFC-VN173 (Addgene). Recombinant plasmids were introduced into NB cells along with Xfect Transfection Reagent (631318, TaKaRa) through co-transfection for a period of 24 h. The confocal microscope (Biocompare, San Francisco, CA) was used to detect fluorescence with excitation (488 nm) and emission (500 nm) wavelengths [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec25"><title>In vitro O-GlcNAcylation assay</title><p>Purified MBP-tagged FOXC1 (3 &#x003bc;g) was incubated with 5 &#x003bc;g of GST-tagged OGT or recombinant OGA protein (ab153117, Abcam Inc.) in 50 &#x003bc;l of reaction buffer (2 mmol&#x000b7;l<sup>&#x02212;1</sup> UDP-GlcNAc, 12.5 mmol&#x000b7;l<sup>&#x02212;1</sup> MgCl<sub>2</sub>, 1 mmol&#x000b7;l<sup>&#x02212;1</sup> DTT, and 50 mmol&#x000b7;l<sup>&#x02212;1</sup> Tris-HCl, pH 7.5) at 37 &#x000b0;C for 4 h, and then incubated with anti-MBP magnetic beads (MerckMillipore) at 4 &#x000b0;C for 3 h. The recovered proteins were analyzed via Western blotting.</p></sec><sec id="sec26"><title>RIP assay</title><p>The ultraviolet light (254 nm, 200 J/cm<sup>2</sup>) was utilized for cellular cross-linking [<xref rid="B68" ref-type="bibr">68</xref>,<xref rid="B69" ref-type="bibr">69</xref>]. The EZ-Magna RIP RNA-Binding Protein Immunoprecipitation Kit (17-701, Sigma) was utilized for the RIP assay, along with antibodies targeting EIF4A3 (ab180573, Abcam Inc.). Recovered RNA was identified through real-time qRT-PCR using specific primers (Table <xref rid="supplementary-material-1" ref-type="sec">S5</xref>).</p></sec><sec id="sec27"><title>Assay for phase separation in&#x000a0;vitro</title><p>To prepare recombinant proteins, a His-tagged <italic toggle="yes">FOXC1</italic> or <italic toggle="yes">OGT</italic> construct was transformed into BL21 strain (Biovector NTCC Inc., Beijing, China), then purified using Ni-NTA His-Tag Purification Agarose (HY-K0210, MedChemExpress). A phase separation test was conducted on dishes with glass bottoms. In a solution for droplet formation (10% glycerol, 50 mmol&#x000b7;l<sup>&#x02212;1</sup> Tris-HCl, and 1.0 mmol&#x000b7;l<sup>&#x02212;1</sup> dithiothreitol, pH 7.5), proteins (40 &#x003bc;mol&#x000b7;l<sup>&#x02212;1</sup>) were mixed with crowding agent (10% polyethylene glycol 8000) and visualized using a Nikon A1R-SI confocal microscope with oil-immersion lenses [<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec28"><title>Assay for phase separation in&#x000a0;vivo</title><p>Tumor cells growing on glass-bottomed dishes and expressing mCherry-tagged protein or endogenous protein were treated with Hoechst 33342 (HY-15559, MedChemExpress) for 10 min. Cells were observed with a Nikon A1R-SI confocal microscope after 2 PBS rinses. Visible phase separation puncta were identified as those with a diameter greater than 0.5 &#x003bc;m [<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec29"><title>FRAP test</title><p>For in&#x000a0;vitro assay, droplets were exposed to 50% laser power (with 488- and 561-nm pulses) for 10 s, while a Nikon A1R-SI confocal microscope equipped with oil-immersion objectives captured time-series photos. The in&#x000a0;vivo FRAP test was conducted with the utilization of a chamber for live-cell imaging. Laser pulses of 488 and 561 nm were employed to bleach droplets at 50% power for 5 s, followed by the observation of photobleaching recovery for 1 min. By using the FIJI/ImageJ (<ext-link xlink:href="https://imagej.nih.gov/ij" ext-link-type="uri">https://imagej.nih.gov/ij</ext-link>) program, fluorescence intensities were adjusted to match those before photobleaching occurred [<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec30"><title>Measurement of amino acids</title><p>To conduct flux experiments with [U-<sup>13</sup>C<sub>5</sub>] glutamine, cells were grown in glutamine-free medium (Sigma) with 10% FBS and 4 mmol&#x000b7;l<sup>&#x02212;1</sup> [U-<sup>13</sup>C<sub>5</sub>]-glutamine (Cambridge Isotope Labs, Tewksbury, MA) for 18 h. The metabolites were obtained by soaking with a mixture of methanol, acetonitrile, and water (in a ratio of 4.5:4.5:1) for 15 min, and then sonicated for 30 s at 4 &#x000b0;C. The liquid chromatography&#x02013;mass spectrometry analysis was performed on the supernatants. Intracellular asparagine or alanine levels were measured by using the Asparagine Assay Kit (ab273333) or the L-Alanine Assay kit (ab83394, Abcam), respectively.</p></sec><sec id="sec31"><title>Assay for protein synthesis</title><p>Tumor cells were treated by puromycin (10 &#x003bc;g&#x000b7;ml<sup>&#x02212;1</sup>) for a duration of 15 min. Western blotting was used to detect puromycylated peptides with an antibody specific for puromycin (ab315887, Abcam Inc.). The Global Protein Synthesis Assay Kit (ab273286, Abcam Inc.) was used in the OP-Puro labeling assay to observe protein synthesis. Analysis of the percentage of positive cells was conducted to quantify newly synthesized OP-puro-labeled peptides [<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec32"><title>Measurement of GSH/GSSG, GPX4 activity, NADPH/NADP<sup>+</sup>, and liable iron</title><p>Intracellular GSH/GSSG levels, GPX4 activity, and NADPH/NADP<sup>+</sup> ratio were determined by the GSH+GSSG/GSH Assay Kit (ab239709, Abcam), the GPX4 Activity Assay Kit (Elabscience, Houston, TX), or the NADPH/NADP Quantitation Kit (MAK038, Sigma). To monitor liable iron, cells were placed on coverslips, treated with RhoNox-1 (MedChemExpress), and dyed with DAPI (300 nmol&#x000b7;l<sup>&#x02212;1</sup>, Sigma).</p></sec><sec id="sec33"><title>Lipid peroxidation assay</title><p>Flow cytometry was conducted in accordance with previous documentation [<xref rid="B72" ref-type="bibr">72</xref>]. Cells were cultured with 1 &#x003bc;M C11-BODIPY (581/591) probe (RM02821, ABclonal Biotechnology Co., Ltd) for 1 h, and received 2 to 3 rinses with cold PBS. Next, flow cytometry was utilized to measure the fluorescence intensity of 1&#x000a0;&#x000d7; 10<sup>4</sup> cells in each sample, with an excitation wavelength of 488 nm and an emission wavelength of 510 nm. The analysis of results was conducted with FlowJo software (BD Biosciences, Ashland, OR).</p></sec><sec id="sec34"><title>Measurement of mitochondrial membrane potential</title><p>The tetraethylbenzimidazolyl carbocyanine iodide (JC-1) dye (HY-15534, MedChemExpress) was utilized for measuring the mitochondrial membrane potential.</p></sec><sec id="sec35"><title>Transmission electron microscopy</title><p>On 10-cm dishes, tumor cells were plated and treated with 2.5% glutaraldehyde. Following a 2- to 3-h fixation with 1% osmic acid, cells were dried off and paraffin-embedded. Uranyl acetate-lead citrate was employed for staining sections that were 70 nm in thickness. Mitochondria were observed and photographed via transmission electron microscopy (Delong America Inc., Quebec, CA).</p></sec><sec id="sec36"><title>Affinity purification</title><p>The FG beads from Nacalai Tesque, Inc (Kyoto, Japan) were mixed with 20 mmol&#x000b7;l<sup>&#x02212;1</sup> MN in <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylformamide for incubation. Next, beads with MN immobilized (0.5 mg) were mixed with recombinant proteins and kept at 4 &#x000b0;C for 2 h. After that, proteins were washed with 0.5% NP-40 lysis buffer and analyzed using Western blotting [<xref rid="B67" ref-type="bibr">67</xref>].</p></sec><sec id="sec37"><title>DSF assay</title><p>Recombinant GST-tagged OGT-570aa or MBP-tagged FOXC1 proteins were incubated with PBS containing SYPRO Orange dye (Invitrogen). Then, chemical compounds were added into the wells and heated from 40 &#x000b0;C to 90 &#x000b0;C (1 &#x000b0;C per minute), while fluorescence intensity was recorded at each 1 &#x000b0;C increment and graphed against temperature. The melting temperature (<italic toggle="yes">T</italic><sub>m</sub>) of proteins was calculated using the Boltzmann equation [<xref rid="B73" ref-type="bibr">73</xref>].</p></sec><sec id="sec38"><title>In vitro viability studies</title><p>For detecting in&#x000a0;vitro viability, 3&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> tumor cells were placed within 96-well plates, and cell viability was measured via the colorimetric assay with tetrazolium bromide (MTT, MerckMillipore) [<xref rid="B68" ref-type="bibr">68</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec39"><title>In vitro growth assay</title><p>Tumor cells (5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> each well) were combined with 0.05% Nobel agar (Thermo Fisher Scientific Inc.), then placed on 6-well plates with solidified 0.1% Noble agar for 21 days of incubation. Cellular colonies were dyed with 0.5% crystal violet and then enumerated using a microscope [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec40"><title>In vitro invasion assay</title><p>Cellular invasive ability was assessed using Matrigel matrix from BD Science (Sparks, MD) [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>]. Tumor cells deprived of nutrients (1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> each well) were placed in the top compartment of a Transwell insert with 8.0-&#x003bc;m pores (Corning, New York, NY) for 24 h. Invaded cells were dyed using 0.1% crystal violet for a duration of 10 min and then examined under the microscope.</p></sec><sec id="sec41"><title>Animal model</title><p>All animal studies followed the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals and were approved by Experimental Animal Ethics at Huazhong University of Science and Technology (approval number: 2021-3207). Four-week-old BALB/c nude mice were randomly selected for tumor formation or experimental metastasis studies [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>]. In experiments involving treatment of live animals, tumor cells (1&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> or 0.4&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>) that had been modified to produce red fluorescent protein were inserted into the dorsal flanks or tail vein of nude mice. Mice were randomly selected and treated with MN (50 mg/kg/day) through tail vein injection after 1 week, then imaged using the Pearl Impulse small animal imaging system (Licor Biosciences, Lincoln, NE) [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec42"><title>Human tissue samples</title><p>The study of human tissues was granted by the Institutional Review Board of Union Hospital, Tongji Medical College (approval number: 2023-0519). All protocols followed were in line with the guidelines outlined in the Declaration of Helsinki. Every legal guardian of NB patients who had no preoperative chemotherapy or radiotherapy in the past signed a document giving their consent. From September 2023 to September 2024, tumor tissues were obtained during the operation, confirmed by a pathologist, and kept at &#x02212;80 &#x000b0;C. Human dorsal root ganglia were obtained from terminated pregnancies.</p></sec><sec id="sec43"><title>Immunohistochemistry</title><p>Antibodies targeting Ki-67 (PA5-19462, Thermo Fisher Scientific Inc.) or CD31 (MA3100, Thermo Fisher Scientific Inc.) were employed in immunohistochemical staining, and quantitative analysis was conducted as previously outlined [<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec44"><title>Statistical analysis</title><p>The average and standard error of the mean (SEM) were employed to illustrate the data. Cutoff values were established based on the average levels of gene expression. The Student&#x02019;s <italic toggle="yes">t</italic> test or analysis of variance (ANOVA) was applied for comparing differences. Fisher&#x02019;s exact test was used to determine the statistical significance of the overlap between 2 gene lists. The correlation coefficient by Pearson was utilized to investigate the connection of gene expression. The log-rank test was used to determine the difference in survival. Statistical tests were considered significant if false discovery rate-corrected <italic toggle="yes">P</italic> values were less than 0.05 in 2-sided tests.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p><bold>Funding:</bold> This work was supported by the Major Program of National Natural Science Foundation of China (82293663) and the National Natural Science Foundation of China (82072801, 82173316, and 82473092).</p><p><bold>Author contributions:</bold> Q.L., Y.C., and C.Y. conceived and performed most of the experiments. M.T., X.W., D.L., X.L., J.Q., and S.Z. accomplished some of the in&#x000a0;vitro experiments. Q.L. and C.Y. accomplished the in&#x000a0;vivo studies. Q.L. and C.Y. undertook the mining of publicly available datasets. Q.L. wrote the manuscript. L.Z. and Q.T. revised the manuscript. All authors read and approved the final manuscript.</p><p content-type="COI-statement"><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>RNA-seq and polysome profiling data have been deposited in the Gene Expression Omnibus (GEO) database (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link>, accession code: GSE294551 and GSE294552). Publicly available datasets can be found in the following: (i) the GEO database (GSE62564 and GSE209112, <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo</ext-link>); (ii) The Cancer Genome Atlas (TCGA, <ext-link xlink:href="https://portal.gdc.cancer.gov" ext-link-type="uri">https://portal.gdc.cancer.gov</ext-link>); and (iii) the GSEA database (<ext-link xlink:href="https://www.gsea-msigdb.org/gsea/index.jsp" ext-link-type="uri">https://www.gsea-msigdb.org/gsea/index.jsp</ext-link>).</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material position="float" content-type="local-data"><label>Supplementary 1</label><caption><p>Figs. S1 to S12</p><p>Tables S1 to S7</p></caption><media xlink:href="research.0703.f1.pdf"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pinto</surname>
<given-names>NR</given-names></string-name>, <string-name><surname>Applebaum</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Volchenboum</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Matthay</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>London</surname>
<given-names>WB</given-names></string-name>, <string-name><surname>Ambros</surname>
<given-names>PF</given-names></string-name>, <string-name><surname>Nakagawara</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Berthold</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Schleiermacher</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JR</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Advances in risk classification and treatment strategies for neuroblastoma</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>27</issue>):<fpage>3008</fpage>&#x02013;<lpage>3017</lpage>.<pub-id pub-id-type="pmid">26304901</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>He</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>PTBP2-mediated alternative splicing of IRF9 controls tumor-associated monocyte/macrophage chemotaxis and repolarization in neuroblastoma progression</article-title>. <source>Research</source>. <year>2023</year>;<volume>6</volume>:<fpage>0033</fpage>.<pub-id pub-id-type="pmid">37040518</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dixon</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Lemberg</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Lamprecht</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Skouta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zaitsev</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Gleason</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>DN</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Cantley</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>WS</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Ferroptosis: An iron-dependent form of nonapoptotic cell death</article-title>. <source>Cell</source>. <year>2012</year>;<volume>149</volume>(<issue>5</issue>):<fpage>1060</fpage>&#x02013;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">22632970</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stockwell</surname>
<given-names>BR</given-names></string-name>, <string-name><surname>Friedmann Angeli</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Bayir</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Bush</surname>
<given-names>AI</given-names></string-name>,<string-name><surname>Conrad</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dixon</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Fulda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gasc&#x000f3;n</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hatzios</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Kagan</surname>
<given-names>VE</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease</article-title>. <source>Cell</source>. <year>2017</year>;<volume>171</volume>(<issue>2</issue>):<fpage>273</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">28985560</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Min</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>F</given-names></string-name></person-group>. 
<article-title>Hepatic HDAC3 regulates systemic iron homeostasis and ferroptosis via the hippo signaling pathway</article-title>. <source>Research</source>. <year>2023</year>;<volume>6</volume>:<fpage>0281</fpage>.<pub-id pub-id-type="pmid">38034086</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dixon</surname>
<given-names>SJ</given-names></string-name></person-group>. 
<article-title>Epigenetic regulation of ferroptosis in the liver</article-title>. <source>Research</source>. <year>2024</year>;<volume>7</volume>:<fpage>0323</fpage>.<pub-id pub-id-type="pmid">38384329</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>F</given-names></string-name></person-group>. 
<article-title>An overview of heavy chain ferritin in cancer</article-title>. <source>Front Biosci</source>. <year>2023</year>;<volume>28</volume>(<issue>8</issue>):<fpage>182</fpage>.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Lotze</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Zeh</surname>
<given-names>HJ</given-names>
<suffix>III</suffix></string-name>, <string-name><surname>Kang</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>D</given-names></string-name></person-group>. 
<article-title>Autophagy promotes ferroptosis by degradation of ferritin</article-title>. <source>Autophagy</source>. <year>2016</year>;<volume>12</volume>(<issue>8</issue>):<fpage>1425</fpage>&#x02013;<lpage>1428</lpage>.<pub-id pub-id-type="pmid">27245739</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dai</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Bi</surname>
<given-names>F</given-names></string-name></person-group>. 
<article-title>Regulation of ferroptosis by amino acid metabolism in cancer</article-title>. <source>Int J Biol Sci</source>. <year>2022</year>;<volume>18</volume>(<issue>4</issue>):<fpage>1695</fpage>&#x02013;<lpage>1705</lpage>.<pub-id pub-id-type="pmid">35280684</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shimada</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Skouta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kaplan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Hayano</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dixon</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Valenzuela</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Wolpaw</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Stockwell</surname>
<given-names>BR</given-names></string-name></person-group>. 
<article-title>Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis</article-title>. <source>Nat Chem Biol</source>. <year>2016</year>;<volume>12</volume>(<issue>7</issue>):<fpage>497</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">27159577</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hayano</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Corn</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Pagano</surname>
<given-names>NC</given-names></string-name>, <string-name><surname>Stockwell</surname>
<given-names>BR</given-names></string-name></person-group>. 
<article-title>Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation</article-title>. <source>Cell Death Differ</source>. <year>2016</year>;<volume>23</volume>(<issue>2</issue>):<fpage>270</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">26184909</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erd&#x000e9;lyi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ditr&#x000f3;i</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Johansson</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Czikora</surname>
<given-names>&#x000c1;</given-names></string-name>, <string-name><surname>Balog</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Silwal-Pandit</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ida</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Olasz</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hajd&#x000fa;</surname>
<given-names>D</given-names></string-name>, <string-name><surname>M&#x000e1;trai</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>45</issue>):
<elocation-id>e2100050118</elocation-id>.<pub-id pub-id-type="pmid">34737229</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>C</given-names></string-name></person-group>. 
<article-title>Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance</article-title>. <source>Br J Cancer</source>. <year>2020</year>;<volume>122</volume>(<issue>2</issue>):<fpage>279</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">31819185</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szabo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Coletta</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chao</surname>
<given-names>C</given-names></string-name>, <string-name><surname>M&#x000f3;dis</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Szczesny</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Papapetropoulos</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hellmich</surname>
<given-names>MR</given-names></string-name></person-group>. 
<article-title>Tumor-derived hydrogen sulfide, produced by cystathionine-&#x003b2;-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2013</year>;<volume>110</volume>(<issue>30</issue>):<fpage>12474</fpage>&#x02013;<lpage>12479</lpage>.<pub-id pub-id-type="pmid">23836652</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takano</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sarfraz</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gilkes</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Chaturvedi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Suematsu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zagzag</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Semenza</surname>
<given-names>GL</given-names></string-name></person-group>. 
<article-title>Decreased expression of cystathionine &#x003b2;-synthase promotes glioma tumorigenesis</article-title>. <source>Mol Cancer Res</source>. <year>2014</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1398</fpage>&#x02013;<lpage>1406</lpage>.<pub-id pub-id-type="pmid">24994751</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bhowmick</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Qu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chung</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Giuliano</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>X</given-names></string-name></person-group>. 
<article-title>FOXC1: An emerging marker and therapeutic target for cancer</article-title>. <source>Oncogene</source>. <year>2017</year>;<volume>36</volume>(<issue>28</issue>):<fpage>3957</fpage>&#x02013;<lpage>3963</lpage>.<pub-id pub-id-type="pmid">28288141</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Qi</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nie</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>57</volume>(<issue>2</issue>):<fpage>610</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">22911555</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shao</surname>
<given-names>QS</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>YY</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>LH</given-names></string-name></person-group>. 
<article-title>Overexpression of FOXC1 correlates with poor prognosis in gastric cancer patients</article-title>. <source>Histopathology</source>. <year>2014</year>;<volume>64</volume>(<issue>7</issue>):<fpage>963</fpage>&#x02013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">24329718</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Geng</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>X</given-names></string-name></person-group>. 
<article-title>A novel long non-coding RNA FOXCUT and mRNA FOXC1 pair promote progression and predict poor prognosis in esophageal squamous cell carcinoma</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2014</year>;<volume>7</volume>(<issue>6</issue>):<fpage>2838</fpage>&#x02013;<lpage>2849</lpage>.<pub-id pub-id-type="pmid">25031703</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><prefix>van der</prefix>
<surname>Heul-Nieuwenhuijsen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Dits</surname>
<given-names>NF</given-names></string-name>, <string-name><surname>Jenster</surname>
<given-names>G</given-names></string-name></person-group>. 
<article-title>Gene expression of forkhead transcription factors in the normal and diseased human prostate</article-title>. <source>BJU Int</source>. <year>2009</year>;<volume>103</volume>(<issue>11</issue>):<fpage>1574</fpage>&#x02013;<lpage>1580</lpage>.<pub-id pub-id-type="pmid">19220249</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sizemore</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Keri</surname>
<given-names>RA</given-names></string-name></person-group>. 
<article-title>The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>29</issue>):<fpage>24631</fpage>&#x02013;<lpage>24640</lpage>.<pub-id pub-id-type="pmid">22645147</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Xia</surname>
<given-names>L</given-names></string-name></person-group>. 
<article-title>Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice</article-title>. <source>Gastroenterology</source>. <year>2015</year>;<volume>149</volume>(<issue>4</issue>):<fpage>1053</fpage>&#x02013;<lpage>1067</lpage>.<pub-id pub-id-type="pmid">26065367</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Qu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Wawrowsky</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bose</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer</article-title>. <source>Cell Rep</source>. <year>2015</year>;<volume>13</volume>(<issue>5</issue>):<fpage>1046</fpage>&#x02013;<lpage>1058</lpage>.<pub-id pub-id-type="pmid">26565916</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berry</surname>
<given-names>FB</given-names></string-name>, <string-name><surname>Mirzayans</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Walter</surname>
<given-names>MA</given-names></string-name></person-group>. 
<article-title>Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>15</issue>):<fpage>10098</fpage>&#x02013;<lpage>10104</lpage>.<pub-id pub-id-type="pmid">16492674</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Danciu</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Chupreta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cruz</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Fox</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Whitman</surname>
<given-names>M</given-names></string-name>, <string-name><surname>I&#x000f1;iguez-Lluh&#x000ed;</surname>
<given-names>JA</given-names></string-name></person-group>. 
<article-title>Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>22</issue>):<fpage>18318</fpage>&#x02013;<lpage>18329</lpage>.<pub-id pub-id-type="pmid">22493429</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vucicevic</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Misirkic</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ciric</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Martinovic</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Jovanovic</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Isakovic</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Markovic</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Saponjic</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Foretz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rabanal-Ruiz</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Transcriptional block of AMPK-induced autophagy promotes glutamate excitotoxicity in nutrient-deprived SH-SY5Y neuroblastoma cells</article-title>. <source>Cell Mol Life Sci</source>. <year>2020</year>;<volume>77</volume>(<issue>17</issue>):<fpage>3383</fpage>&#x02013;<lpage>3399</lpage>.<pub-id pub-id-type="pmid">31720741</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kritis</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Stamoula</surname>
<given-names>EG</given-names></string-name>, <string-name><surname>Paniskaki</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Vavilis</surname>
<given-names>TD</given-names></string-name></person-group>. 
<article-title>Researching glutamate-induced cytotoxicity in different cell lines: A comparative/collective analysis/study</article-title>. <source>Front Cell Neurosci</source>. <year>2015</year>;<volume>9</volume>:<fpage>91</fpage>.<pub-id pub-id-type="pmid">25852482</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keenan</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Torre</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lachmann</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Leong</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Wojciechowicz</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Utti</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Jagodnik</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Kropiwnicki</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Ma&#x02019;ayan</surname>
<given-names>A</given-names></string-name></person-group>. 
<article-title>ChEA3: Transcription factor enrichment analysis by orthogonal omics integration</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>(<issue>W1</issue>):<fpage>W212</fpage>&#x02013;<lpage>W224</lpage>.<pub-id pub-id-type="pmid">31114921</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lomelino</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Andring</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>McKenna</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kilberg</surname>
<given-names>MS</given-names></string-name></person-group>. 
<article-title>Asparagine synthetase: Function, structure, and role in disease</article-title>. <source>J Biol Chem</source>. <year>2017</year>;<volume>292</volume>(<issue>49</issue>):<fpage>19952</fpage>&#x02013;<lpage>19958</lpage>.<pub-id pub-id-type="pmid">29084849</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>RZ</given-names></string-name>, <string-name><surname>Blaileanu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Hansen</surname>
<given-names>BC</given-names></string-name>, <string-name><surname>Shuldiner</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Gong</surname>
<given-names>DW</given-names></string-name></person-group>. 
<article-title>cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase</article-title>. <source>Genomics</source>. <year>2002</year>;<volume>79</volume>(<issue>3</issue>):<fpage>445</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">11863375</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gong</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kong</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>J</given-names></string-name></person-group>. 
<article-title>Identification of a ferritinophagy inducer via sinomenine modification for the treatment of colorectal cancer</article-title>. <source>Eur J Med Chem</source>. <year>2024</year>;<volume>268</volume>:
<elocation-id>116250</elocation-id>.<pub-id pub-id-type="pmid">38417218</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>He</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>SY</given-names></string-name></person-group>. 
<article-title>The HDOCK server for integrated protein-protein docking</article-title>. <source>Nat Protoc</source>. <year>2020</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1829</fpage>&#x02013;<lpage>1852</lpage>.<pub-id pub-id-type="pmid">32269383</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Dunbrack</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Dunker</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Uversky</surname>
<given-names>VN</given-names></string-name></person-group>. 
<article-title>PONDR-FIT: A meta-predictor of intrinsically disordered amino acids</article-title>. <source>Biochim Biophys Acta</source>. <year>2010</year>;<volume>1804</volume>(<issue>4</issue>):<fpage>996</fpage>&#x02013;<lpage>1010</lpage>.<pub-id pub-id-type="pmid">20100603</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ulianov</surname>
<given-names>SV</given-names></string-name>, <string-name><surname>Velichko</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Magnitov</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Luzhin</surname>
<given-names>AV</given-names></string-name>, <string-name><surname>Golov</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Ovsyannikova</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kireev</surname>
<given-names>II</given-names></string-name>, <string-name><surname>Gavrikov</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Mishin</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Garaev</surname>
<given-names>AK</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Suppression of liquid-liquid phase separation by 1,6-hexanediol partially compromises the 3D genome organization in living cells</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>;<volume>49</volume>(<issue>18</issue>):<fpage>10524</fpage>&#x02013;<lpage>10541</lpage>.<pub-id pub-id-type="pmid">33836078</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ortiz-Meoz</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lazarus</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Orman</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Janetzko</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Duveau</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>ZW</given-names></string-name>, <string-name><surname>Thomas</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Walker</surname>
<given-names>S</given-names></string-name></person-group>. 
<article-title>A small molecule that inhibits OGT activity in cells</article-title>. <source>ACS Chem Biol</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>1392</fpage>&#x02013;<lpage>1397</lpage>.<pub-id pub-id-type="pmid">25751766</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuzwa</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Shan</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Macauley</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Clark</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Skorobogatko</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Vosseller</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Vocadlo</surname>
<given-names>DJ</given-names></string-name></person-group>. 
<article-title>Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation</article-title>. <source>Nat Chem Biol</source>. <year>2012</year>;<volume>8</volume>(<issue>4</issue>):<fpage>393</fpage>&#x02013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">22366723</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hou</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>C</given-names></string-name></person-group>. 
<article-title>O-GlcNAcPRED-DL: Prediction of protein O-GlcNAcylation sites based on an ensemble model of deep learning</article-title>. <source>J Proteome Res</source>. <year>2024</year>;<volume>23</volume>(<issue>1</issue>):<fpage>95</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">38054441</pub-id>
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conn</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Chinnaiyan</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Conn</surname>
<given-names>SJ</given-names></string-name></person-group>. 
<article-title>Circular RNA in cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2024</year>;<volume>24</volume>(<issue>9</issue>):<fpage>597</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">39075222</pub-id>
</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gla&#x0017e;ar</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Papavasileiou</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rajewsky</surname>
<given-names>N</given-names></string-name></person-group>. 
<article-title>circBase: A database for circular RNAs</article-title>. <source>RNA</source>. <year>2014</year>;<volume>20</volume>(<issue>11</issue>):<fpage>1666</fpage>&#x02013;<lpage>1670</lpage>.<pub-id pub-id-type="pmid">25234927</pub-id>
</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ge</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Guan</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Ju</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>L</given-names></string-name></person-group>. 
<article-title>Molecular interplay between EIF4 family and circular RNAs in cancer: Mechanisms and therapeutics</article-title>. <source>Eur J Pharmacol</source>. <year>2023</year>;<volume>954</volume>:
<elocation-id>175867</elocation-id>.<pub-id pub-id-type="pmid">37369297</pub-id>
</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ito</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ando</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Suzuki</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ogura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hotta</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Imamura</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yamaguchi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Handa</surname>
<given-names>H</given-names></string-name></person-group>. 
<article-title>Identification of a primary target of thalidomide teratogenicity</article-title>. <source>Science</source>. <year>2010</year>;<volume>327</volume>(<issue>5971</issue>):<fpage>1345</fpage>&#x02013;<lpage>1350</lpage>.<pub-id pub-id-type="pmid">20223979</pub-id>
</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoo</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Quan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Rodr&#x000ed;guez</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chalmers</surname>
<given-names>ZR</given-names></string-name>, <string-name><surname>Dufficy</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Lackie</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Sagar</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Unno</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Asparagine dependency is a targetable metabolic vulnerability in TP53-altered castration-resistant prostate cancer</article-title>. <source>Cancer Res</source>. <year>2024</year>;<volume>84</volume>(<issue>18</issue>):<fpage>3004</fpage>&#x02013;<lpage>3022</lpage>.<pub-id pub-id-type="pmid">38959335</pub-id>
</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>LW</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>YX</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>YF</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>ZW</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>TY</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma</article-title>. <source>Br J Cancer</source>. <year>2013</year>;<volume>109</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">23764751</pub-id>
</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lv</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>X</given-names></string-name></person-group>. 
<article-title>Loss of asparagine synthetase suppresses the growth of human lung cancer cells by arresting cell cycle at G0/G1 phase</article-title>. <source>Cancer Gene Ther</source>. <year>2016</year>;<volume>23</volume>(<issue>9</issue>):<fpage>287</fpage>&#x02013;<lpage>294</lpage>.<pub-id pub-id-type="pmid">27444726</pub-id>
</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kumanova</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hart</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Sloane</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>De Panis</surname>
<given-names>DN</given-names></string-name>, <string-name><surname>Bobrovnikova-Marjon</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Diehl</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Ron</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Koumenis</surname>
<given-names>C</given-names></string-name></person-group>. 
<article-title>The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation</article-title>. <source>EMBO J</source>. <year>2010</year>;<volume>29</volume>(<issue>12</issue>):<fpage>2082</fpage>&#x02013;<lpage>2096</lpage>.<pub-id pub-id-type="pmid">20473272</pub-id>
</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srivastava</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Misra</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Seim</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Staschke</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Zhong</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Dav&#x000e9;</surname>
<given-names>U</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Asparagine bioavailability regulates the translation of MYC oncogene</article-title>. <source>Oncogene</source>. <year>2022</year>;<volume>41</volume>(<issue>44</issue>):<fpage>4855</fpage>&#x02013;<lpage>4865</lpage>.<pub-id pub-id-type="pmid">36182969</pub-id>
</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chin</surname>
<given-names>YE</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mi</surname>
<given-names>J</given-names></string-name></person-group>. 
<article-title>Glutamic pyruvate transaminase GPT2 promotes tumorigenesis of breast cancer cells by activating sonic hedgehog signaling</article-title>. <source>Theranostics</source>. <year>2017</year>;<volume>7</volume>(<issue>12</issue>):<fpage>3021</fpage>&#x02013;<lpage>3033</lpage>.<pub-id pub-id-type="pmid">28839461</pub-id>
</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Dai</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>G</given-names></string-name></person-group>. 
<article-title>Enhanced glutamine utilization mediated by SLC1A5 and GPT2 is an essential metabolic feature of colorectal signet ring cell carcinoma with therapeutic potential</article-title>. <source>Ann Transl Med</source>. <year>2020</year>;<volume>8</volume>(<issue>6</issue>):<fpage>302</fpage>.<pub-id pub-id-type="pmid">32355746</pub-id>
</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>YY</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>LP</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>ZJ</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>QX</given-names></string-name>, <string-name><surname>Zhuang</surname>
<given-names>ZZ</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>XJ</given-names></string-name></person-group>. 
<article-title>Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer</article-title>. <source>Mol Med</source>. <year>2019</year>;<volume>25</volume>(<issue>1</issue>):<fpage>47</fpage>.<pub-id pub-id-type="pmid">31706267</pub-id>
</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pei</surname>
<given-names>H</given-names></string-name></person-group>. 
<article-title>Targeting O-GlcNAcylation in cancer therapeutic resistance: The sugar saga continues</article-title>. <source>Cancer Lett</source>. <year>2024</year>;<volume>588</volume>:
<elocation-id> 216742</elocation-id>.<pub-id pub-id-type="pmid">38401884</pub-id>
</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>(<issue>9</issue>):<fpage>1890</fpage>&#x02013;<lpage>1904</lpage>.<pub-id pub-id-type="pmid">33657401</pub-id>
</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kupfer</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Pei</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Direct stimulation of de novo nucleotide synthesis by O-GlcNAcylation</article-title>. <source>Nat Chem Biol</source>. <year>2024</year>;<volume>20</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">37308732</pub-id>
</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Zhen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Qian</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Regulation of the hippo-YAP pathway by glucose sensor O-GlcNAcylation</article-title>. <source>Mol Cell</source>. <year>2017</year>;<volume>68</volume>(<issue>3</issue>):<fpage>591</fpage>&#x02013;<lpage>604.e5</lpage>.<pub-id pub-id-type="pmid">29100056</pub-id>
</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lou</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gong</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name></person-group>. 
<article-title>O-GlcNAcylation and stabilization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REG&#x003b3; interaction</article-title>. <source>Cell Death Differ</source>. <year>2022</year>;<volume>29</volume>(<issue>10</issue>):<fpage>1970</fpage>&#x02013;<lpage>1981</lpage>.<pub-id pub-id-type="pmid">35422493</pub-id>
</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-&#x003ba;B/bone remodeling factors signaling</article-title>. <source>Mol Cancer</source>. <year>2021</year>;<volume>20</volume>(<issue>1</issue>):<fpage>98</fpage>.<pub-id pub-id-type="pmid">34325714</pub-id>
</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>L</given-names></string-name></person-group>. 
<article-title>EIF4A3-regulated circ_0087429 can reverse EMT and inhibit the progression of cervical cancer via miR-5003-3p-dependent upregulation of OGN expression</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2022</year>;<volume>41</volume>(<issue>1</issue>):<fpage>165</fpage>.<pub-id pub-id-type="pmid">35513835</pub-id>
</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duan</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Nie</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Mei</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>ZC</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>FW</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma</article-title>. <source>Mol Cancer</source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>93</fpage>.<pub-id pub-id-type="pmid">35366894</pub-id>
</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rahman</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Wo&#x00142;czy&#x00144;ski</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer</article-title>. <source>Mol Cancer</source>. <year>2023</year>;<volume>22</volume>(<issue>1</issue>):<fpage>104</fpage>.<pub-id pub-id-type="pmid">37408008</pub-id>
</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>J</given-names></string-name></person-group>. 
<article-title>A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via hippo-YAP signaling</article-title>. <source>Mol Cancer</source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>47</fpage>.<pub-id pub-id-type="pmid">30925892</pub-id>
</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR</article-title>. <source>Mol Cancer</source>. <year>2023</year>;<volume>22</volume>(<issue>1</issue>):<fpage>16</fpage>.<pub-id pub-id-type="pmid">36691031</pub-id>
</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeo</surname>
<given-names>IJ</given-names></string-name>, <string-name><surname>Yun</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Son</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>JT</given-names></string-name></person-group>. 
<article-title>Antifungal drug miconazole ameliorated memory deficits in a mouse model of LPS-induced memory loss through targeting iNOS</article-title>. <source>Cell Death Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>8</issue>):<fpage>623</fpage>.<pub-id pub-id-type="pmid">32796824</pub-id>
</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Togashi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Inada</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tominaga</surname>
<given-names>M</given-names></string-name></person-group>. 
<article-title>Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB)</article-title>. <source>Br J Pharmacol</source>. <year>2008</year>;<volume>153</volume>(<issue>6</issue>):<fpage>1324</fpage>&#x02013;<lpage>1330</lpage>.<pub-id pub-id-type="pmid">18204483</pub-id>
</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Jeng</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Tseng</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>SY</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2002</year>;<volume>180</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">11922774</pub-id>
</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Shiau</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Ou</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Chiu</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>KJ</given-names></string-name></person-group>. 
<article-title>Miconazole induces apoptosis via the death receptor 5-dependent and mitochondrial-mediated pathways in human bladder cancer cells</article-title>. <source>Oncol Rep</source>. <year>2017</year>;<volume>37</volume>(<issue>6</issue>):<fpage>3606</fpage>&#x02013;<lpage>3616</lpage>.<pub-id pub-id-type="pmid">28498480</pub-id>
</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Jung</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Seo</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Jha</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Suh</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Suh</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Baek</surname>
<given-names>WK</given-names></string-name></person-group>. 
<article-title>Translational suppression of HIF-1&#x003b1; by miconazole through the mTOR signaling pathway</article-title>. <source>Cell Oncol</source>. <year>2014</year>;<volume>37</volume>(<issue>4</issue>):<fpage>269</fpage>&#x02013;<lpage>279</lpage>.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>HT</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Jiann</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Chiang</surname>
<given-names>AJ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Effect of miconazole on intracellular Ca<sup>2+</sup> levels and proliferation in human osteosarcoma cells</article-title>. <source>Life Sci</source>. <year>2005</year>;<volume>76</volume>(<issue>18</issue>):<fpage>2091</fpage>&#x02013;<lpage>2101</lpage>.<pub-id pub-id-type="pmid">15826876</pub-id>
</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression</article-title>. <source>Clin Transl Med</source>. <year>2024</year>;<volume>14</volume>(<issue>5</issue>):
<elocation-id>Article e1680</elocation-id>.<pub-id pub-id-type="pmid">38769668</pub-id>
</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jiao</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2023</year>;<volume>42</volume>(<issue>1</issue>):<fpage>313</fpage>.<pub-id pub-id-type="pmid">37993881</pub-id>
</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity</article-title>. <source>Oncogene</source>. <year>2023</year>;<volume>42</volume>(<issue>36</issue>):<fpage>2673</fpage>&#x02013;<lpage>2687</lpage>.<pub-id pub-id-type="pmid">37537343</pub-id>
</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity</article-title>. <source>Clin Transl Med</source>. <year>2023</year>;<volume>13</volume>(<issue>4</issue>):
<elocation-id>Article e1235</elocation-id>.<pub-id pub-id-type="pmid">37186134</pub-id>
</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harlow</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lane</surname>
<given-names>D</given-names></string-name></person-group>. 
<article-title>Immunoprecipitation: Preclearing the lysate</article-title>. <source>CSH Protoc</source>. <year>2006</year>;<volume>2006</volume>(<issue>4</issue>):<fpage>pdb.prot4535</fpage>.<pub-id pub-id-type="pmid">22485917</pub-id>
</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>LP</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Guan</surname>
<given-names>ZR</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>YP</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>XQ</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>ZH</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>&#x003b2;-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer</article-title>. <source>J Adv Res</source>. <year>2024</year>;<volume>62</volume>:<fpage>257</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">37689240</pub-id>
</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niesen</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Berglund</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Vedadi</surname>
<given-names>M</given-names></string-name></person-group>. 
<article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title>. <source>Nat Protoc</source>. <year>2007</year>;<volume>2</volume>(<issue>9</issue>):<fpage>2212</fpage>&#x02013;<lpage>2221</lpage>.<pub-id pub-id-type="pmid">17853878</pub-id>
</mixed-citation></ref></ref-list></back></article>